{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:30:40Z","timestamp":1793323840010,"version":"4.5.0"},"reference-count":365,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82371427"],"award-info":[{"award-number":["No.82371427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82401656"],"award-info":[{"award-number":["No.82401656"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-MSX0323"],"award-info":[{"award-number":["CSTB2023NSCQ-MSX0323"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint project of Chongqing Health Commission and Science and Technology Bureau","award":["2025MSXM044"],"award-info":[{"award-number":["2025MSXM044"]}]},{"name":"Postgraduate Research and Project of Chongqing Province","award":["CYB240199"],"award-info":[{"award-number":["CYB240199"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer disease (AD) is the most common neurodegenerative disorder and a leading cause of dementia worldwide. With accelerating population aging, its incidence continues to rise, imposing a substantial burden on public health systems and society. Despite extensive advances in research, currently available therapies remain largely symptomatic and have limited capacity to halt or reverse disease progression. Recent progress in understanding the molecular and cellular mechanisms underlying AD has driven the development of targeted therapeutic strategies, particularly immunotherapies directed against amyloid-\u03b2 (A\u03b2) and tau pathology. However, the pathogenesis of AD is highly complex and multifactorial, underscoring the need for a more integrated understanding of the interactions among diverse pathological processes and the identification of additional therapeutic targets. Here, we provide a systematic synthesis of the core pathological mechanisms of AD and their interconnected molecular pathways, together with a comprehensive overview of current targeted therapeutic strategies. We highlight recent advances in A\u03b2- and tau-directed immunotherapies and further examine emerging interventions targeting neuroinflammation, metabolic dysregulation, the gut microbiota, lifestyle-related factors, and neurogenesis, evaluating their potential based on evidence from both clinical and preclinical studies. By integrating mechanistic insights with therapeutic developments, this review outlines key opportunities and challenges in the evolving landscape of AD treatment. These perspectives may inform the development of next-generation disease-modifying therapies and contribute to a more comprehensive framework for understanding the pathogenesis and treatment of AD.<\/jats:p>","DOI":"10.1186\/s43556-026-00443-2","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T10:24:58Z","timestamp":1775125498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Alzheimer's disease: from molecular pathways to therapies"],"prefix":"10.1186","volume":"7","author":[{"given":"Jing-Qiu","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Xi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Qing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"7","key":"443_CR1","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/jgs.17345","volume":"69","author":"MP Aranda","year":"2021","unstructured":"Aranda MP, Kremer IN, Hinton L, Zissimopoulos J, Whitmer RA, Hummel CH, et al. Impact of dementia: health disparities, population trends, care interventions, and economic costs. J Am Geriatr Soc. 2021;69(7):1774\u201383. https:\/\/doi.org\/10.1111\/jgs.17345.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"443_CR2","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"443_CR3","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3390\/biom15091290","volume":"15","author":"J Li","year":"2025","unstructured":"Li J, Wang L, Zhang X, Shi J, Zhu Y, Wang H, et al. Translating Alzheimer\u2019s Disease Mechanisms into Therapeutic Opportunities. Biomolecules. 2025;15(9):1290. https:\/\/doi.org\/10.3390\/biom15091290.","journal-title":"Biomolecules"},{"issue":"1","key":"443_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40291-024-00738-6","volume":"29","author":"MC Tartaglia","year":"2025","unstructured":"Tartaglia MC, Ingelsson M. Molecular therapeutics in development to treat Alzheimer\u2019s disease. Mol Diagn Ther. 2025;29(1):9\u201324. https:\/\/doi.org\/10.1007\/s40291-024-00738-6.","journal-title":"Mol Diagn Ther"},{"issue":"20","key":"443_CR5","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker M, Walker LC. Alzheimer\u2019s disease: from immunotherapy to immunoprevention. Cell. 2023;186(20):4260\u201370. https:\/\/doi.org\/10.1016\/j.cell.2023.08.021.","journal-title":"Cell"},{"issue":"2","key":"443_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Wang X. Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell. 2025;16(2):83\u2013120. https:\/\/doi.org\/10.1093\/procel\/pwae026.","journal-title":"Protein Cell"},{"issue":"1","key":"443_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjmed.2024.08.019","volume":"138","author":"EJ Goetzl","year":"2025","unstructured":"Goetzl EJ. Current developments in Alzheimer\u2019s disease. Am J Med. 2025;138(1):15\u201320. https:\/\/doi.org\/10.1016\/j.amjmed.2024.08.019.","journal-title":"Am J Med"},{"issue":"3","key":"443_CR8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/s0006-291x(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW. Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120(3):885\u201390. https:\/\/doi.org\/10.1016\/s0006-291x(84)80190-4.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5054","key":"443_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135. https:\/\/doi.org\/10.1126\/science.1566067.","journal-title":"Science"},{"issue":"10","key":"443_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-v","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12(10):383\u20138. https:\/\/doi.org\/10.1016\/0165-6147(91)90609-v.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"443_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","volume":"10","author":"K Shoghi-Jadid","year":"2002","unstructured":"Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10(1):24\u201335.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"443_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.14336\/AD.2023.0608","volume":"15","author":"M Nasb","year":"2024","unstructured":"Nasb M, Tao W, Chen N. Alzheimer\u2019s Disease Puzzle: Delving into Pathogenesis Hypotheses. Aging Dis. 2024;15(1):43\u201373. https:\/\/doi.org\/10.14336\/AD.2023.0608.","journal-title":"Aging Dis"},{"issue":"6","key":"443_CR13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/alz.12463","volume":"18","author":"M Sawa","year":"2022","unstructured":"Sawa M, Overk C, Becker A, Derse D, Albay R, Weldy K, et al. Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. Alzheimers Dement. 2022;18(6):1203\u201334. https:\/\/doi.org\/10.1002\/alz.12463.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"443_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","volume":"23","author":"GB Frisoni","year":"2022","unstructured":"Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022;23(1):53\u201366. https:\/\/doi.org\/10.1038\/s41583-021-00533-w.","journal-title":"Nat Rev Neurosci"},{"key":"443_CR15","doi-asserted-by":"publisher","first-page":"102161","DOI":"10.1016\/j.arr.2023.102161","volume":"93","author":"A Granzotto","year":"2024","unstructured":"Granzotto A, Sensi SL. Once upon a time, the Amyloid Cascade Hypothesis. Ageing Res Rev. 2024;93:102161. https:\/\/doi.org\/10.1016\/j.arr.2023.102161.","journal-title":"Ageing Res Rev"},{"issue":"19","key":"443_CR16","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1021\/acs.accounts.3c00370","volume":"56","author":"A Abelein","year":"2023","unstructured":"Abelein A. Metal binding of Alzheimer\u2019s amyloid-beta and its effect on peptide self-assembly. Acc Chem Res. 2023;56(19):2653\u201363. https:\/\/doi.org\/10.1021\/acs.accounts.3c00370.","journal-title":"Acc Chem Res"},{"issue":"1","key":"443_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13041-024-01118-1","volume":"17","author":"A Azargoonjahromi","year":"2024","unstructured":"Azargoonjahromi A. The duality of amyloid-beta: its role in normal and Alzheimer\u2019s disease states. Mol Brain. 2024;17(1):44. https:\/\/doi.org\/10.1186\/s13041-024-01118-1.","journal-title":"Mol Brain"},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"137532","DOI":"10.1016\/j.neulet.2023.137532","volume":"817","author":"A Gholami","year":"2023","unstructured":"Gholami A. Alzheimer\u2019s disease: the role of proteins in formation, mechanisms, and new therapeutic approaches. Neurosci Lett. 2023;817:137532. https:\/\/doi.org\/10.1016\/j.neulet.2023.137532.","journal-title":"Neurosci Lett"},{"issue":"11","key":"443_CR19","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414\u201324. https:\/\/doi.org\/10.1093\/brain\/awad188.","journal-title":"Brain"},{"issue":"6","key":"443_CR20","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1038\/s41380-025-02911-7","volume":"30","author":"J Hardy","year":"2025","unstructured":"Hardy J, Escott-Price V. The genetics of neurodegenerative diseases is the genetics of age-related damage clearance failure. Mol Psychiatry. 2025;30(6):2748\u201353. https:\/\/doi.org\/10.1038\/s41380-025-02911-7.","journal-title":"Mol Psychiatry"},{"issue":"9","key":"443_CR21","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.1007\/s12035-018-0914-2","volume":"55","author":"R Coronel","year":"2018","unstructured":"Coronel R, Bernabeu-Zornoza A, Palmer C, Muniz-Moreno M, Zambrano A, Cano E, et al. Role of Amyloid Precursor Protein (APP) and its derivatives in the biology and cell fate specification of neural stem cells. Mol Neurobiol. 2018;55(9):7107\u201317. https:\/\/doi.org\/10.1007\/s12035-018-0914-2.","journal-title":"Mol Neurobiol"},{"key":"443_CR22","doi-asserted-by":"publisher","unstructured":"Kurkinen M, Fulek M, Fulek K, Beszlej JA, Kurpas D, Leszek J. The Amyloid Cascade Hypothesis in Alzheimer's Disease: Should We Change Our Thinking? Biomolecules. 2023;13(3). https:\/\/doi.org\/10.3390\/biom13030453.","DOI":"10.3390\/biom13030453"},{"issue":"7","key":"443_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrn2168","volume":"8","author":"FM LaFerla","year":"2007","unstructured":"LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer\u2019s disease. Nat Rev Neurosci. 2007;8(7):499\u2013509. https:\/\/doi.org\/10.1038\/nrn2168.","journal-title":"Nat Rev Neurosci"},{"issue":"21","key":"443_CR24","doi-asserted-by":"publisher","first-page":"12924","DOI":"10.3390\/ijms232112924","volume":"23","author":"U Sehar","year":"2022","unstructured":"Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH. Amyloid Beta in Aging and Alzheimer\u2019s Disease. Int J Mol Sci. 2022;23(21):12924. https:\/\/doi.org\/10.3390\/ijms232112924.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"443_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00702-003-0091-x","volume":"111","author":"A Salehi","year":"2004","unstructured":"Salehi A, Delcroix JD, Swaab DF. Alzheimer\u2019s disease and NGF signaling. J Neural Transm. 2004;111(3):323\u201345. https:\/\/doi.org\/10.1007\/s00702-003-0091-x.","journal-title":"J Neural Transm"},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijbiomac.2020.11.192","volume":"167","author":"H Ashrafian","year":"2021","unstructured":"Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer\u2019s disease: inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol. 2021;167:382\u201394. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.11.192.","journal-title":"Int J Biol Macromol"},{"key":"443_CR27","doi-asserted-by":"publisher","unstructured":"Morito T, Hashimoto S, Takamura R, Watamura N, Kakiya N, Fujioka R, et al. The Role of Neprilysin and Insulin-Degrading Enzyme in the Etiology of Sporadic Alzheimer's Disease. J Neurosci. 2025;45(23). https:\/\/doi.org\/10.1523\/JNEUROSCI.2152-24.2025.","DOI":"10.1523\/JNEUROSCI.2152-24.2025"},{"issue":"3 Pt 1","key":"443_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/wnl.42.3.631","volume":"42","author":"PV Arriagada","year":"1992","unstructured":"Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology. 1992;42(3 Pt 1):631\u20139. https:\/\/doi.org\/10.1212\/wnl.42.3.631.","journal-title":"Neurology"},{"issue":"1","key":"443_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410410106","volume":"41","author":"T Gomez-Isla","year":"1997","unstructured":"Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease. Ann Neurol. 1997;41(1):17\u201324. https:\/\/doi.org\/10.1002\/ana.410410106.","journal-title":"Ann Neurol"},{"issue":"9","key":"443_CR30","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/alz.12321","volume":"17","author":"CM Moloney","year":"2021","unstructured":"Moloney CM, Lowe VJ, Murray ME. Visualization of neurofibrillary tangle maturity in Alzheimer\u2019s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement. 2021;17(9):1554\u201374. https:\/\/doi.org\/10.1002\/alz.12321.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"443_CR31","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","volume":"72","author":"MD Weingarten","year":"1975","unstructured":"Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975;72(5):1858\u201362. https:\/\/doi.org\/10.1073\/pnas.72.5.1858.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"443_CR32","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3390\/ijms15034671","volume":"15","author":"A Mietelska-Porowska","year":"2014","unstructured":"Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G. Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci. 2014;15(3):4671\u2013713. https:\/\/doi.org\/10.3390\/ijms15034671.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"443_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/cm.21812","volume":"81","author":"M Goedert","year":"2024","unstructured":"Goedert M, Crowther RA, Scheres SHW, Spillantini MG. Tau and neurodegeneration. Cytoskeleton (Hoboken). 2024;81(1):95\u2013102. https:\/\/doi.org\/10.1002\/cm.21812.","journal-title":"Cytoskeleton (Hoboken)"},{"issue":"6","key":"443_CR34","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","volume":"183","author":"H Wesseling","year":"2020","unstructured":"Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P, et al. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer\u2019s Disease. Cell. 2020;183(6):1699-713 e13. https:\/\/doi.org\/10.1016\/j.cell.2020.10.029.","journal-title":"Cell"},{"issue":"8","key":"443_CR35","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.str.2015.06.002","volume":"23","author":"M Schwalbe","year":"2015","unstructured":"Schwalbe M, Kadavath H, Biernat J, Ozenne V, Blackledge M, Mandelkow E, et al. Structural impact of tau phosphorylation at threonine 231. Structure. 2015;23(8):1448\u201358. https:\/\/doi.org\/10.1016\/j.str.2015.06.002.","journal-title":"Structure"},{"issue":"10","key":"443_CR36","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1021\/acs.j.pcb.9b11720","volume":"124","author":"L Rani","year":"2020","unstructured":"Rani L, Mittal J, Mallajosyula SS. Effect of phosphorylation and O-GlcNAcylation on proline-rich domains of tau. J Phys Chem B. 2020;124(10):1909\u201318. https:\/\/doi.org\/10.1021\/acs.j.pcb.9b11720.","journal-title":"J Phys Chem B"},{"issue":"1","key":"443_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00401-025-02862-x","volume":"149","author":"H Braak","year":"2025","unstructured":"Braak H, Mayer B, Feldengut S, Schon M, Del Tredici K. Sequence and trajectory of early Alzheimer\u2019s disease-related tau inclusions in the hippocampal formation of cases without amyloid-\u03b2 deposits. Acta Neuropathol. 2025;149(1):50. https:\/\/doi.org\/10.1007\/s00401-025-02862-x.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"443_CR38","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/00005072-199609000-00003","volume":"55","author":"B Hempen","year":"1996","unstructured":"Hempen B, Brion JP. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer\u2019s disease. J Neuropathol Exp Neurol. 1996;55(9):964\u201372. https:\/\/doi.org\/10.1097\/00005072-199609000-00003.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"443_CR39","doi-asserted-by":"publisher","first-page":"101442","DOI":"10.1016\/j.jbc.2021.101442","volume":"298","author":"DM Acosta","year":"2022","unstructured":"Acosta DM, Mancinelli C, Bracken C, Eliezer D. Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation. J Biol Chem. 2022;298(1):101442. https:\/\/doi.org\/10.1016\/j.jbc.2021.101442.","journal-title":"J Biol Chem"},{"key":"443_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1750-1326-4-13","volume":"4","author":"TF Gendron","year":"2009","unstructured":"Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener. 2009;4:13. https:\/\/doi.org\/10.1186\/1750-1326-4-13.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"443_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuron.2018.06.003","volume":"99","author":"A Ittner","year":"2018","unstructured":"Ittner A, Ittner LM. Dendritic tau in Alzheimer\u2019s disease. Neuron. 2018;99(1):13\u201327. https:\/\/doi.org\/10.1016\/j.neuron.2018.06.003.","journal-title":"Neuron"},{"issue":"1","key":"443_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5\u201321. https:\/\/doi.org\/10.1038\/nrn.2015.1.","journal-title":"Nat Rev Neurosci"},{"issue":"52","key":"443_CR43","doi-asserted-by":"publisher","first-page":"36406","DOI":"10.1074\/jbc.M803519200","volume":"283","author":"AC LeBoeuf","year":"2008","unstructured":"LeBoeuf AC, Levy SF, Gaylord M, Bhattacharya A, Singh AK, Jordan MA, et al. FTDP-17 mutations in Tau alter the regulation of microtubule dynamics: an \u201calternative core\u201d model for normal and pathological Tau action. J Biol Chem. 2008;283(52):36406\u201315. https:\/\/doi.org\/10.1074\/jbc.M803519200.","journal-title":"J Biol Chem"},{"issue":"1","key":"443_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0306-4522(02)00404-9","volume":"115","author":"WH Zheng","year":"2002","unstructured":"Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid \u03b2 peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002;115(1):201\u201311. https:\/\/doi.org\/10.1016\/s0306-4522(02)00404-9.","journal-title":"Neuroscience"},{"issue":"3","key":"443_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0014-5793(94)01445-7","volume":"358","author":"TJ Singh","year":"1995","unstructured":"Singh TJ, Haque N, Grundke-Iqbal I, Iqbal K. Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett. 1995;358(3):267\u201372. https:\/\/doi.org\/10.1016\/0014-5793(94)01445-7.","journal-title":"FEBS Lett"},{"issue":"32","key":"443_CR46","doi-asserted-by":"publisher","first-page":"24374","DOI":"10.1016\/S0021-9258(20)80536-5","volume":"268","author":"E Kopke","year":"1993","unstructured":"Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem. 1993;268(32):24374\u201384.","journal-title":"J Biol Chem"},{"issue":"2","key":"443_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.arr.2008.11.003","volume":"8","author":"RA Boonen","year":"2009","unstructured":"Boonen RA, van Tijn P, Zivkovic D. Wnt signaling in Alzheimer\u2019s disease: up or down, that is the question. Ageing Res Rev. 2009;8(2):71\u201382. https:\/\/doi.org\/10.1016\/j.arr.2008.11.003.","journal-title":"Ageing Res Rev"},{"key":"443_CR48","doi-asserted-by":"publisher","unstructured":"Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies. Int J Mol Sci. 2022;23(21). https:\/\/doi.org\/10.3390\/ijms232112841.","DOI":"10.3390\/ijms232112841"},{"issue":"4","key":"443_CR49","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/0896-6273(94)90264-x","volume":"13","author":"ES Matsuo","year":"1994","unstructured":"Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O\u2019Connor M, Trojanowski JQ, et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer\u2019s disease paired helical filament tau. Neuron. 1994;13(4):989\u20131002. https:\/\/doi.org\/10.1016\/0896-6273(94)90264-x.","journal-title":"Neuron"},{"key":"443_CR50","doi-asserted-by":"publisher","first-page":"15709","DOI":"10.1038\/srep15709","volume":"5","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhang Y, Hu W, Xie S, Gong CX, Iqbal K, et al. Rapid alteration of protein phosphorylation during postmortem: implication in the study of protein phosphorylation. Sci Rep. 2015;5:15709. https:\/\/doi.org\/10.1038\/srep15709.","journal-title":"Sci Rep"},{"issue":"5","key":"443_CR51","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/j.1471-4159.2008.05300.x","volume":"105","author":"J Platholi","year":"2008","unstructured":"Platholi J, Heerdt PM, Lim Tung HY, Hemmings HC Jr. Activation of brain protein phosphatase-1(I) following cardiac arrest and resuscitation involving an interaction with 14-3-3 gamma. J Neurochem. 2008;105(5):2029\u201338. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05300.x.","journal-title":"J Neurochem"},{"key":"443_CR52","doi-asserted-by":"publisher","unstructured":"Krassner MM, Kauffman J, Sowa A, Cialowicz K, Walsh S, Farrell K, et al. Postmortem changes in brain cell structure: a review. Free Neuropathol. 2023;4:10. https:\/\/doi.org\/10.17879\/freeneuropathology-2023-4790.","DOI":"10.17879\/freeneuropathology-2023-4790"},{"issue":"4","key":"443_CR53","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1002\/alz.13737","volume":"20","author":"D Datta","year":"2024","unstructured":"Datta D, Perone I, Wijegunawardana D, Liang F, Morozov YM, Arellano J, et al. 11Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration. Alzheimer\u2019s Dementia. 2024;20(4):2843\u201360. https:\/\/doi.org\/10.1002\/alz.13737.","journal-title":"Alzheimer's Dementia"},{"issue":"2","key":"443_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41593-024-01829-7","volume":"28","author":"N Watamura","year":"2025","unstructured":"Watamura N, Foiani MS, Bez S, Bourdenx M, Santambrogio A, Frodsham C, et al. In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds. Nat Neurosci. 2025;28(2):293\u2013307. https:\/\/doi.org\/10.1038\/s41593-024-01829-7.","journal-title":"Nat Neurosci"},{"issue":"14","key":"443_CR55","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1016\/j.cell.2025.04.006","volume":"188","author":"SS Harris","year":"2025","unstructured":"Harris SS, Ellingford R, Hartmann J, Dasgupta D, Kehring M, Rajani RM, et al. Alzheimer\u2019s disease patient-derived high-molecular-weight tau impairs bursting in hippocampal neurons. Cell. 2025;188(14):3775-88 e21. https:\/\/doi.org\/10.1016\/j.cell.2025.04.006.","journal-title":"Cell"},{"issue":"2","key":"443_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/brain\/aww230","volume":"140","author":"M Goedert","year":"2017","unstructured":"Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration. Brain. 2017;140(2):266\u201378. https:\/\/doi.org\/10.1093\/brain\/aww230.","journal-title":"Brain"},{"issue":"14","key":"443_CR57","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1016\/j.cell.2025.06.016","volume":"188","author":"LV Lopes","year":"2025","unstructured":"Lopes LV, Pousinha PA. Burst firing in Alzheimer\u2019s disease: a shift beyond amyloid? Cell. 2025;188(14):3629\u201330. https:\/\/doi.org\/10.1016\/j.cell.2025.06.016.","journal-title":"Cell"},{"issue":"7","key":"443_CR58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14(7):399\u2013415. https:\/\/doi.org\/10.1038\/s41582-018-0013-z.","journal-title":"Nat Rev Neurol"},{"issue":"4 Suppl","key":"443_CR59","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/s0197-4580(97)00062-6","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer\u2019s disease. Neurobiol Aging. 1997;18(4 Suppl):S85\u20138. https:\/\/doi.org\/10.1016\/s0197-4580(97)00062-6.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"443_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrn2786","volume":"11","author":"B Frost","year":"2010","unstructured":"Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11(3):155\u20139. https:\/\/doi.org\/10.1038\/nrn2786.","journal-title":"Nat Rev Neurosci"},{"issue":"5707","key":"443_CR61","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1126\/science.1105850","volume":"307","author":"AT Petkova","year":"2005","unstructured":"Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer\u2019s beta-amyloid fibrils. Science. 2005;307(5707):262\u20135. https:\/\/doi.org\/10.1126\/science.1105850.","journal-title":"Science"},{"key":"443_CR62","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-med-042921-023749","volume":"74","author":"B Hyman","year":"2023","unstructured":"Hyman B. All the tau we cannot see. Annu Rev Med. 2023;74:503\u201314. https:\/\/doi.org\/10.1146\/annurev-med-042921-023749.","journal-title":"Annu Rev Med"},{"issue":"5733","key":"443_CR63","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K Santacruz","year":"2005","unstructured":"Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476\u201381. https:\/\/doi.org\/10.1126\/science.1113694.","journal-title":"Science"},{"issue":"7","key":"443_CR64","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/NEN.0b013e318220a658","volume":"70","author":"LM Fox","year":"2011","unstructured":"Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, et al. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol. 2011;70(7):588\u201395. https:\/\/doi.org\/10.1097\/NEN.0b013e318220a658.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"443_CR65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00401-013-1215-5","volume":"127","author":"M Polydoro","year":"2014","unstructured":"Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, et al. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer\u2019s disease model. Acta Neuropathol. 2014;127(2):257\u201370. https:\/\/doi.org\/10.1007\/s00401-013-1215-5.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"443_CR66","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/nn.3199","volume":"15","author":"N Rudinskiy","year":"2012","unstructured":"Rudinskiy N, Hawkes JM, Betensky RA, Eguchi M, Yamaguchi S, Spires-Jones TL, et al. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer\u2019s disease. Nat Neurosci. 2012;15(10):1422\u20139. https:\/\/doi.org\/10.1038\/nn.3199.","journal-title":"Nat Neurosci"},{"issue":"3","key":"443_CR67","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"LM Ittner","year":"2010","unstructured":"Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models. Cell. 2010;142(3):387\u201397. https:\/\/doi.org\/10.1016\/j.cell.2010.06.036.","journal-title":"Cell"},{"issue":"6","key":"443_CR68","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ana.24394","volume":"77","author":"AC Kaufman","year":"2015","unstructured":"Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol. 2015;77(6):953\u201371. https:\/\/doi.org\/10.1002\/ana.24394.","journal-title":"Ann Neurol"},{"issue":"4","key":"443_CR69","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","volume":"83","author":"HB Nygaard","year":"2018","unstructured":"Nygaard HB. Targeting Fyn kinase in Alzheimer\u2019s disease. Biol Psychiatry. 2018;83(4):369\u201376. https:\/\/doi.org\/10.1016\/j.biopsych.2017.06.004.","journal-title":"Biol Psychiatry"},{"issue":"7","key":"443_CR70","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/mp.2016.38","volume":"21","author":"D Campion","year":"2016","unstructured":"Campion D, Pottier C, Nicolas G, Le Guennec K, Rovelet-Lecrux A. Alzheimer disease: modeling an Abeta-centered biological network. Mol Psychiatry. 2016;21(7):861\u201371. https:\/\/doi.org\/10.1038\/mp.2016.38.","journal-title":"Mol Psychiatry"},{"key":"443_CR71","doi-asserted-by":"publisher","unstructured":"Datta D, Perone I, Wijegunawardana D, Liang F, Morozov YM, Arellano J, et al. Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.11.07.566046.","DOI":"10.1101\/2023.11.07.566046"},{"issue":"2","key":"443_CR72","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-016-1558-9","volume":"132","author":"KR Sadleir","year":"2016","unstructured":"Sadleir KR, Kandalepas PC, Buggia-Prevot V, Nicholson DA, Thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A\u03b2 generation in Alzheimer\u2019s disease. Acta Neuropathol. 2016;132(2):235\u201356. https:\/\/doi.org\/10.1007\/s00401-016-1558-9.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"443_CR73","doi-asserted-by":"publisher","first-page":"e70882","DOI":"10.1002\/alz.70882","volume":"21","author":"S Oveisgharan","year":"2025","unstructured":"Oveisgharan S, Yu L, Wang Y, Yang J, Vialle R, Lopes KP, et al. 13Amyloid beta binding partners in the brain tissue of older adults. Alzheimer\u2019s Dementia. 2025;21(11):e70882. https:\/\/doi.org\/10.1002\/alz.70882.","journal-title":"Alzheimer's Dementia"},{"issue":"3","key":"443_CR74","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2353\/ajpath.2008.070904","volume":"172","author":"D Terwel","year":"2008","unstructured":"Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, et al. 14Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol. 2008;172(3):786\u201398. https:\/\/doi.org\/10.2353\/ajpath.2008.070904.","journal-title":"Am J Pathol"},{"issue":"1","key":"443_CR75","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/JAD-2009-0933","volume":"16","author":"P Hernandez","year":"2009","unstructured":"Hernandez P, Lee G, Sjoberg M, Maccioni RB. 15Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts. J Alzheimers Dis. 2009;16(1):149\u201356. https:\/\/doi.org\/10.3233\/JAD-2009-0933.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"443_CR76","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1002\/j.1460-2075.1992.tb05272.x","volume":"11","author":"G Drewes","year":"1992","unstructured":"Drewes G, Lichtenberg-Kraag B, Doring F, Mandelkow EM, Biernat J, Goris J, et al. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 1992;11(6):2131\u20138. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05272.x.","journal-title":"EMBO J"},{"issue":"2","key":"443_CR77","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1242\/jcs.01655","volume":"118","author":"C Feijoo","year":"2005","unstructured":"Feijoo C, Campbell DG, Jakes R, Goedert M, Cuenda A. 17Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4\/p38delta at Thr50 promotes microtubule assembly. J Cell Sci. 2005;118(2):397\u2013408. https:\/\/doi.org\/10.1242\/jcs.01655.","journal-title":"J Cell Sci"},{"issue":"10","key":"443_CR78","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.biopsych.2014.12.019","volume":"78","author":"U Sengupta","year":"2015","unstructured":"Sengupta U, Guerrero-Munoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, et al. 18Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry. 2015;78(10):672\u201383. https:\/\/doi.org\/10.1016\/j.biopsych.2014.12.019.","journal-title":"Biol Psychiatry"},{"issue":"17","key":"443_CR79","doi-asserted-by":"publisher","first-page":"10032","DOI":"10.1073\/pnas.1630428100","volume":"100","author":"TC Gamblin","year":"2003","unstructured":"Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2003;100(17):10032\u20137. https:\/\/doi.org\/10.1073\/pnas.1630428100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"443_CR80","doi-asserted-by":"publisher","first-page":"14893","DOI":"10.1074\/jbc.M115.652693","volume":"290","author":"H Mirbaha","year":"2015","unstructured":"Mirbaha H, Holmes BB, Sanders DW, Bieschke J, Diamond MI. Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J Biol Chem. 2015;290(24):14893\u2013903. https:\/\/doi.org\/10.1074\/jbc.M115.652693.","journal-title":"J Biol Chem"},{"issue":"7","key":"443_CR81","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/mp.2016.38","volume":"21","author":"D Campion","year":"2016","unstructured":"Campion D, Pottier C, Nicolas G, Le Guennec K, Rovelet-Lecrux A. 21Alzheimer disease: modeling an Abeta-centered biological network. Mol Psychiatry. 2016;21(7):861\u201371. https:\/\/doi.org\/10.1038\/mp.2016.38.","journal-title":"Mol Psychiatry"},{"key":"443_CR82","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimer\u2019s & Dement (N Y). 2018;4:575\u201390. https:\/\/doi.org\/10.1016\/j.trci.2018.06.014.","journal-title":"Alzheimer's & Dement (N Y)"},{"key":"443_CR83","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/NDT.S75546","volume":"11","author":"F Zhang","year":"2015","unstructured":"Zhang F, Jiang L. Neuroinflammation in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat. 2015;11:243\u201356. https:\/\/doi.org\/10.2147\/NDT.S75546.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"443_CR84","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2174\/1567205014666170203141717","volume":"14","author":"F Regen","year":"2017","unstructured":"Regen F, Hellmann-Regen J, Costantini E, Reale M. Neuroinflammation and Alzheimer\u2019s disease: implications for microglial activation. Curr Alzheimer Res. 2017;14(11):1140\u20138. https:\/\/doi.org\/10.2174\/1567205014666170203141717.","journal-title":"Curr Alzheimer Res"},{"key":"443_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/JIR.S86958","volume":"9","author":"MR Bronzuoli","year":"2016","unstructured":"Bronzuoli MR, Iacomino A, Steardo L, Scuderi C. Targeting neuroinflammation in Alzheimer\u2019s disease. J Inflamm Res. 2016;9:199\u2013208. https:\/\/doi.org\/10.2147\/JIR.S86958.","journal-title":"J Inflamm Res"},{"issue":"3","key":"443_CR86","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jnc.13411","volume":"136","author":"MR Minter","year":"2016","unstructured":"Minter MR, Taylor JM, Crack PJ. The contribution of neuroinflammation to amyloid toxicity in Alzheimer\u2019s disease. J Neurochem. 2016;136(3):457\u201374. https:\/\/doi.org\/10.1111\/jnc.13411.","journal-title":"J Neurochem"},{"issue":"7784","key":"443_CR87","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669\u201373. https:\/\/doi.org\/10.1038\/s41586-019-1769-z.","journal-title":"Nature"},{"issue":"1","key":"443_CR88","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s40478-019-0828-x","volume":"7","author":"DK Franco-Bocanegra","year":"2019","unstructured":"Franco-Bocanegra DK, George B, Lau LC, Holmes C, Nicoll JAR, Boche D. Microglial motility in Alzheimer\u2019s disease and after A\u03b242 immunotherapy: a human post-mortem study. Acta Neuropathol Commun. 2019;7(1):174. https:\/\/doi.org\/10.1186\/s40478-019-0828-x.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"443_CR89","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","volume":"139","author":"L Hamelin","year":"2016","unstructured":"Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer\u2019s disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139(4):1252\u201364. https:\/\/doi.org\/10.1093\/brain\/aww017.","journal-title":"Brain"},{"issue":"8","key":"443_CR90","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/wnl.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology. 1988;38(8):1285\u201391. https:\/\/doi.org\/10.1212\/wnl.38.8.1285.","journal-title":"Neurology"},{"issue":"5","key":"443_CR91","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2990.2010.01156.x","volume":"37","author":"E Zotova","year":"2011","unstructured":"Zotova E, Holmes C, Johnston D, Neal JW, Nicoll JA, Boche D. Microglial alterations in human Alzheimer\u2019s disease following A\u03b242 immunization. Neuropathol Appl Neurobiol. 2011;37(5):513\u201324. https:\/\/doi.org\/10.1111\/j.1365-2990.2010.01156.x.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"443_CR92","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fimmu.2012.00089","volume":"3","author":"S Jung","year":"2012","unstructured":"Jung S, Schwartz M. Non-identical twins - microglia and monocyte-derived macrophages in acute injury and autoimmune inflammation. Front Immunol. 2012;3:89. https:\/\/doi.org\/10.3389\/fimmu.2012.00089.","journal-title":"Front Immunol"},{"key":"443_CR93","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbi.2013.02.005","volume":"32","author":"V Chhor","year":"2013","unstructured":"Chhor V, Le Charpentier T, Lebon S, Ore MV, Celador IL, Josserand J, et al. 38Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 2013;32:70\u201385. https:\/\/doi.org\/10.1016\/j.bbi.2013.02.005.","journal-title":"Brain Behav Immun"},{"issue":"1","key":"443_CR94","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nan.12011","volume":"39","author":"D Boche","year":"2013","unstructured":"Boche D, Perry VH, Nicoll JA. 39Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol. 2013;39(1):3\u201318. https:\/\/doi.org\/10.1111\/nan.12011.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"443_CR95","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbi.2013.02.005","volume":"32","author":"V Chhor","year":"2013","unstructured":"Chhor V, Le Charpentier T, Lebon S, Ore MV, Celador IL, Josserand J, et al. 40Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 2013;32:70\u201385. https:\/\/doi.org\/10.1016\/j.bbi.2013.02.005.","journal-title":"Brain Behav Immun"},{"key":"443_CR96","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pharmthera.2015.06.010","volume":"154","author":"Y Nakagawa","year":"2015","unstructured":"Nakagawa Y, Chiba K. Diversity and plasticity of microglial cells in psychiatric and neurological disorders. Pharmacol Ther. 2015;154:21\u201335. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.06.010.","journal-title":"Pharmacol Ther"},{"key":"443_CR97","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pneurobio.2015.05.003","volume":"131","author":"R Franco","year":"2015","unstructured":"Franco R, Fernandez-Suarez D. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol. 2015;131:65\u201386. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.05.003.","journal-title":"Prog Neurobiol"},{"key":"443_CR98","doi-asserted-by":"publisher","unstructured":"Chauhan P, Sheng WS, Hu S, Prasad S, Lokensgard JR. 43Differential Cytokine-Induced Responses of Polarized Microglia. Brain Sci. 2021;11(11). https:\/\/doi.org\/10.3390\/brainsci11111482.","DOI":"10.3390\/brainsci11111482"},{"issue":"3","key":"443_CR99","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1096\/fj.02-0314fje","volume":"17","author":"H Wilms","year":"2003","unstructured":"Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. 47activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson\u2019s disease. FASEB J. 2003;17(3):500\u20132. https:\/\/doi.org\/10.1096\/fj.02-0314fje.","journal-title":"FASEB J"},{"issue":"1","key":"443_CR100","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10456-013-9381-6","volume":"17","author":"N Jetten","year":"2014","unstructured":"Jetten N, Verbruggen S, Gijbels MJ, Post MJ, De Winther MP, Donners MM. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis. 2014;17(1):109\u201318. https:\/\/doi.org\/10.1007\/s10456-013-9381-6.","journal-title":"Angiogenesis"},{"issue":"2","key":"443_CR101","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","volume":"53","author":"Y Tang","year":"2016","unstructured":"Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53(2):1181\u201394. https:\/\/doi.org\/10.1007\/s12035-014-9070-5.","journal-title":"Mol Neurobiol"},{"key":"443_CR102","doi-asserted-by":"publisher","first-page":"856376","DOI":"10.3389\/fimmu.2022.856376","volume":"13","author":"Y Cai","year":"2022","unstructured":"Cai Y, Liu J, Wang B, Sun M, Yang H. Microglia in the Neuroinflammatory Pathogenesis of Alzheimer\u2019s Disease and Related Therapeutic Targets. Front Immunol. 2022;13:856376. https:\/\/doi.org\/10.3389\/fimmu.2022.856376.","journal-title":"Front Immunol"},{"issue":"4","key":"443_CR103","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.stem.2010.08.014","volume":"7","author":"A Sierra","year":"2010","unstructured":"Sierra A, Encinas JM, Deudero JJ, Chancey JH, Enikolopov G, Overstreet-Wadiche LS, et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell. 2010;7(4):483\u201395. https:\/\/doi.org\/10.1016\/j.stem.2010.08.014.","journal-title":"Cell Stem Cell"},{"issue":"11","key":"443_CR104","doi-asserted-by":"publisher","first-page":"e1000527","DOI":"10.1371\/journal.pbio.1000527","volume":"8","author":"ME Tremblay","year":"2010","unstructured":"Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 2010;8(11):e1000527. https:\/\/doi.org\/10.1371\/journal.pbio.1000527.","journal-title":"PLoS Biol"},{"issue":"3","key":"443_CR105","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s11481-013-9434-z","volume":"8","author":"UB Eyo","year":"2013","unstructured":"Eyo UB, Dailey ME. Microglia: key elements in neural development, plasticity, and pathology. J Neuroimmune Pharmacol. 2013;8(3):494\u2013509. https:\/\/doi.org\/10.1007\/s11481-013-9434-z.","journal-title":"J Neuroimmune Pharmacol"},{"key":"443_CR106","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.bbi.2016.08.018","volume":"59","author":"WC Pierre","year":"2017","unstructured":"Pierre WC, Smith PLP, Londono I, Chemtob S, Mallard C, Lodygensky GA. Neonatal microglia: the cornerstone of brain fate. Brain Behav Immun. 2017;59:333\u201345. https:\/\/doi.org\/10.1016\/j.bbi.2016.08.018.","journal-title":"Brain Behav Immun"},{"issue":"11","key":"443_CR107","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.4103\/1673-5374.371368","volume":"18","author":"J Qiu","year":"2023","unstructured":"Qiu J, Guo J, Liu L, Liu X, Sun X, Chen H. Vav1 promotes inflammation and neuronal apoptosis in cerebral ischemia\/reperfusion injury by upregulating microglial and NLRP3 inflammasome activation. Neural Regen Res. 2023;18(11):2436\u201342. https:\/\/doi.org\/10.4103\/1673-5374.371368.","journal-title":"Neural Regen Res"},{"issue":"3","key":"443_CR108","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jalz.2018.10.006","volume":"15","author":"F Xiong","year":"2019","unstructured":"Xiong F, Ge W, Ma C. Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer\u2019s disease. Alzheimers Dement. 2019;15(3):429\u201340. https:\/\/doi.org\/10.1016\/j.jalz.2018.10.006.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"443_CR109","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1038\/s41467-024-54779-w","volume":"15","author":"N Baligacs","year":"2024","unstructured":"Baligacs N, Albertini G, Borrie SC, Serneels L, Pridans C, Balusu S, et al. Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer\u2019s Disease. Nat Commun. 2024;15(1):10634. https:\/\/doi.org\/10.1038\/s41467-024-54779-w.","journal-title":"Nat Commun"},{"issue":"5","key":"443_CR110","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41590-021-00913-5","volume":"22","author":"Y Huang","year":"2021","unstructured":"Huang Y, Happonen KE, Burrola PG, O\u2019Connor C, Hah N, Huang L, et al. 58Microglia use TAM receptors to detect and engulf amyloid beta plaques. Nat Immunol. 2021;22(5):586\u201394. https:\/\/doi.org\/10.1038\/s41590-021-00913-5.","journal-title":"Nat Immunol"},{"issue":"14","key":"443_CR111","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1007\/s00253-020-10614-y","volume":"104","author":"W Li","year":"2020","unstructured":"Li W, Cao T, Luo C, Cai J, Zhou X, Xiao X, et al. Crosstalk between ER stress, NLRP3 inflammasome, and inflammation. Appl Microbiol Biotechnol. 2020;104(14):6129\u201340. https:\/\/doi.org\/10.1007\/s00253-020-10614-y.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"3","key":"443_CR112","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2015.08.008","volume":"43","author":"DN Bronner","year":"2015","unstructured":"Bronner DN, Abuaita BH, Chen X, Fitzgerald KA, Nunez G, He Y, et al. Endoplasmic reticulum stress activates the inflammasome via NLRP3- and caspase-2-driven mitochondrial damage. Immunity. 2015;43(3):451\u201362. https:\/\/doi.org\/10.1016\/j.immuni.2015.08.008.","journal-title":"Immunity"},{"issue":"5","key":"443_CR113","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/jb\/mvw009","volume":"159","author":"X Jin","year":"2016","unstructured":"Jin X, Yamashita T. Microglia in central nervous system repair after injury. J Biochem. 2016;159(5):491\u20136. https:\/\/doi.org\/10.1093\/jb\/mvw009.","journal-title":"J Biochem"},{"key":"443_CR114","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1750-1326-6-45","volume":"6","author":"XD Pan","year":"2011","unstructured":"Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, et al. Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer\u2019s disease. Mol Neurodegener. 2011;6:45. https:\/\/doi.org\/10.1186\/1750-1326-6-45.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"443_CR115","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1172\/JCI58642","volume":"122","author":"R Deane","year":"2012","unstructured":"Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGE-specific inhibitor reduces amyloid \u03b2\u2013mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122(4):1377\u201392. https:\/\/doi.org\/10.1172\/JCI58642.","journal-title":"J Clin Invest"},{"issue":"7685","key":"443_CR116","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, et al. Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer\u2019s disease. Nature. 2017;552(7685):355\u201361. https:\/\/doi.org\/10.1038\/nature25158.","journal-title":"Nature"},{"issue":"43","key":"443_CR117","doi-asserted-by":"publisher","first-page":"eabg4980","DOI":"10.1126\/sciadv.abg4980","volume":"7","author":"JH Brelstaff","year":"2021","unstructured":"Brelstaff JH, Mason M, Katsinelos T, McEwan WA, Ghetti B, Tolkovsky AM, et al. Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates. Sci Adv. 2021;7(43):eabg4980. https:\/\/doi.org\/10.1126\/sciadv.abg4980.","journal-title":"Sci Adv"},{"issue":"3","key":"443_CR118","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4103\/1673-5374.320970","volume":"17","author":"Y Ju","year":"2022","unstructured":"Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer\u2019s disease. Neural Regen Res. 2022;17(3):543\u20139. https:\/\/doi.org\/10.4103\/1673-5374.320970.","journal-title":"Neural Regen Res"},{"issue":"4","key":"443_CR119","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-018-01957-y","volume":"137","author":"IC Stancu","year":"2019","unstructured":"Stancu IC, Cremers N, Vanrusselt H, Couturier J, Vanoosthuyse A, Kessels S, et al. Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol. 2019;137(4):599\u2013617. https:\/\/doi.org\/10.1007\/s00401-018-01957-y.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"443_CR120","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer\u2019s Disease. Cell. 2017;169(7):1276-90 e17. https:\/\/doi.org\/10.1016\/j.cell.2017.05.018.","journal-title":"Cell"},{"issue":"5","key":"443_CR121","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41593-024-01600-y","volume":"27","author":"R Mancuso","year":"2024","unstructured":"Mancuso R, Fattorelli N, Martinez-Muriana A, Davis E, Wolfs L, Van Den Daele J, et al. 73Xenografted human microglia display diverse transcriptomic states in response to Alzheimer\u2019s disease-related amyloid-beta pathology. Nat Neurosci. 2024;27(5):886\u2013900. https:\/\/doi.org\/10.1038\/s41593-024-01600-y.","journal-title":"Nat Neurosci"},{"issue":"7","key":"443_CR122","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s43587-023-00424-y","volume":"3","author":"KE Prater","year":"2023","unstructured":"Prater KE, Green KJ, Mamde S, Sun W, Cochoit A, Smith CL, et al. Human microglia show unique transcriptional changes in Alzheimer\u2019s disease. Nat Aging. 2023;3(7):894\u2013907. https:\/\/doi.org\/10.1038\/s43587-023-00424-y.","journal-title":"Nat Aging"},{"issue":"22","key":"443_CR123","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1016\/j.cell.2022.09.033","volume":"185","author":"S Wang","year":"2022","unstructured":"Wang S, Sudan R, Peng V, Zhou Y, Du S, Yuede CM, et al. TREM2 drives microglia response to amyloid-\u03b2 via SYK-dependent and -independent pathways. Cell. 2022;185(22):4153-69 e19. https:\/\/doi.org\/10.1016\/j.cell.2022.09.033. (75).","journal-title":"Cell"},{"issue":"22","key":"443_CR124","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1016\/j.cell.2022.09.030","volume":"185","author":"H Ennerfelt","year":"2022","unstructured":"Ennerfelt H, Frost EL, Shapiro DA, Holliday C, Zengeler KE, Voithofer G, et al. SYK coordinates neuroprotective microglial responses in neurodegenerative disease. Cell. 2022;185(22):4135-52 e22. https:\/\/doi.org\/10.1016\/j.cell.2022.09.030. (76).","journal-title":"Cell"},{"issue":"7","key":"443_CR125","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41593-023-01355-y","volume":"26","author":"Z Yin","year":"2023","unstructured":"Yin Z, Herron S, Silveira S, Kleemann K, Gauthier C, Mallah D, et al. 78Identification of a protective microglial state mediated by miR-155 and interferon-gamma signaling in a mouse model of Alzheimer\u2019s disease. Nat Neurosci. 2023;26(7):1196\u2013207. https:\/\/doi.org\/10.1038\/s41593-023-01355-y.","journal-title":"Nat Neurosci"},{"key":"443_CR126","doi-asserted-by":"publisher","first-page":"111438","DOI":"10.1016\/j.mad.2021.111438","volume":"195","author":"Q Qin","year":"2021","unstructured":"Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang Y. 79TREM2, microglia, and Alzheimer\u2019s disease. Mech Ageing Dev. 2021;195:111438. https:\/\/doi.org\/10.1016\/j.mad.2021.111438.","journal-title":"Mech Ageing Dev"},{"issue":"7","key":"443_CR127","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41593-023-01355-y","volume":"26","author":"Z Yin","year":"2023","unstructured":"Yin Z, Herron S, Silveira S, Kleemann K, Gauthier C, Mallah D, et al. 82Identification of a protective microglial state mediated by miR-155 and interferon-gamma signaling in a mouse model of Alzheimer\u2019s disease. Nat Neurosci. 2023;26(7):1196\u2013207. https:\/\/doi.org\/10.1038\/s41593-023-01355-y.","journal-title":"Nat Neurosci"},{"issue":"1","key":"443_CR128","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13024-022-00562-8","volume":"17","author":"B Zhu","year":"2022","unstructured":"Zhu B, Liu Y, Hwang S, Archuleta K, Huang H, Campos A, et al. 83Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. Mol Neurodegener. 2022;17(1):58. https:\/\/doi.org\/10.1186\/s13024-022-00562-8.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"443_CR129","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13024-018-0254-8","volume":"13","author":"S Rangaraju","year":"2018","unstructured":"Rangaraju S, Dammer EB, Raza SA, Rathakrishnan P, Xiao H, Gao T, et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer\u2019s disease. Mol Neurodegener. 2018;13(1):24. https:\/\/doi.org\/10.1186\/s13024-018-0254-8.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"443_CR130","doi-asserted-by":"publisher","first-page":"e12753","DOI":"10.1111\/nan.12753","volume":"48","author":"L Viejo","year":"2022","unstructured":"Viejo L, Noori A, Merrill E, Das S, Hyman BT, Serrano-Pozo A. 86Systematic review of human post-mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer\u2019s disease. Neuropathol Appl Neurobiol. 2022;48(1):e12753. https:\/\/doi.org\/10.1111\/nan.12753.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7","key":"443_CR131","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med. 2018;24(7):931\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0051-5.","journal-title":"Nat Med"},{"issue":"7638","key":"443_CR132","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. 89Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481\u20137. https:\/\/doi.org\/10.1038\/nature21029.","journal-title":"Nature"},{"issue":"6","key":"443_CR133","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41593-020-0624-8","volume":"23","author":"N Habib","year":"2020","unstructured":"Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, et al. 90Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat Neurosci. 2020;23(6):701\u20136. https:\/\/doi.org\/10.1038\/s41593-020-0624-8.","journal-title":"Nat Neurosci"},{"issue":"1","key":"443_CR134","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41591-019-0695-9","volume":"26","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer\u2019s disease. Nat Med. 2020;26(1):131\u201342. https:\/\/doi.org\/10.1038\/s41591-019-0695-9.","journal-title":"Nat Med"},{"issue":"9","key":"443_CR135","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41556-024-01429-4","volume":"26","author":"HL Glover","year":"2024","unstructured":"Glover HL, Schreiner A, Dewson G, Tait SWG. 92Mitochondria and cell death. Nat Cell Biol. 2024;26(9):1434\u201346. https:\/\/doi.org\/10.1038\/s41556-024-01429-4.","journal-title":"Nat Cell Biol"},{"key":"443_CR136","doi-asserted-by":"publisher","first-page":"875989","DOI":"10.3389\/fnagi.2022.875989","volume":"14","author":"M Reutzel","year":"2022","unstructured":"Reutzel M, Grewal R, Joppe A, Eckert GP. Age-dependent alterations of cognition, mitochondrial function, and beta-amyloid deposition in a murine model of Alzheimer\u2019s disease-a longitudinal study. Front Aging Neurosci. 2022;14:875989. https:\/\/doi.org\/10.3389\/fnagi.2022.875989.","journal-title":"Front Aging Neurosci"},{"key":"443_CR137","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.freeradbiomed.2021.07.013","volume":"172","author":"H Morton","year":"2021","unstructured":"Morton H, Kshirsagar S, Orlov E, Bunquin LE, Sawant N, Boleng L, et al. Defective mitophagy and synaptic degeneration in Alzheimer\u2019s disease: focus on aging, mitochondria and synapse. Free Radic Biol Med. 2021;172:652\u201367. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.07.013.","journal-title":"Free Radic Biol Med"},{"key":"443_CR138","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.ceca.2020.102344","volume":"94","author":"S Antonucci","year":"2021","unstructured":"Antonucci S, Di Lisa F, Kaludercic N. 96Mitochondrial reactive oxygen species in physiology and disease. Cell Calcium. 2021;94:102344. https:\/\/doi.org\/10.1016\/j.ceca.2020.102344.","journal-title":"Cell Calcium"},{"key":"443_CR139","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.ceca.2020.102344","volume":"94","author":"S Antonucci","year":"2021","unstructured":"Antonucci S, Di Lisa F, Kaludercic N. 97Mitochondrial reactive oxygen species in physiology and disease. Cell Calcium. 2021;94:102344. https:\/\/doi.org\/10.1016\/j.ceca.2020.102344.","journal-title":"Cell Calcium"},{"issue":"7","key":"443_CR140","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s12035-020-01926-1","volume":"57","author":"G Monzio Compagnoni","year":"2020","unstructured":"Monzio Compagnoni G, Di Fonzo A, Corti S, Comi GP, Bresolin N, Masliah E. 98The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer\u2019s Disease and Parkinson\u2019s Disease. Mol Neurobiol. 2020;57(7):2959\u201380. https:\/\/doi.org\/10.1007\/s12035-020-01926-1.","journal-title":"Mol Neurobiol"},{"issue":"12","key":"443_CR141","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1089\/ars.2011.4149","volume":"16","author":"RH Swerdlow","year":"2012","unstructured":"Swerdlow RH. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer\u2019s disease. Antioxid Redox Signal. 2012;16(12):1434\u201355. https:\/\/doi.org\/10.1089\/ars.2011.4149.","journal-title":"Antioxid Redox Signal"},{"key":"443_CR142","doi-asserted-by":"publisher","first-page":"119985","DOI":"10.1016\/j.lfs.2021.119985","volume":"285","author":"S Mani","year":"2021","unstructured":"Mani S, Swargiary G, Singh M, Agarwal S, Dey A, Ojha S, et al. Mitochondrial defects: an emerging theranostic avenue towards Alzheimer\u2019s associated dysregulations. Life Sci. 2021;285:119985. https:\/\/doi.org\/10.1016\/j.lfs.2021.119985.","journal-title":"Life Sci"},{"key":"443_CR143","doi-asserted-by":"publisher","unstructured":"Choi EH, Kim MH, Park SJ. 101Targeting Mitochondrial Dysfunction and Reactive Oxygen Species for Neurodegenerative Disease Treatment. Int J Mol Sci. 2024;25(14). https:\/\/doi.org\/10.3390\/ijms25147952.","DOI":"10.3390\/ijms25147952"},{"issue":"21","key":"443_CR144","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3969\/j.issn.1673-5374.2013.21.009","volume":"8","author":"C Guo","year":"2013","unstructured":"Guo C, Sun L, Chen X, Zhang D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res. 2013;8(21):2003\u201314. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2013.21.009.","journal-title":"Neural Regen Res"},{"key":"443_CR145","doi-asserted-by":"publisher","first-page":"1452696","DOI":"10.1155\/2020\/1452696","volume":"2020","author":"S Rius-Perez","year":"2020","unstructured":"Rius-Perez S, Torres-Cuevas I, Millan I, Ortega AL, Perez S. PGC-1alpha, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696. https:\/\/doi.org\/10.1155\/2020\/1452696.","journal-title":"Oxid Med Cell Longev"},{"issue":"13","key":"443_CR146","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1093\/hmg\/ddr139","volume":"20","author":"M Manczak","year":"2011","unstructured":"Manczak M, Calkins MJ, Reddy PH. 107Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer\u2019s disease: implications for neuronal damage. Hum Mol Genet. 2011;20(13):2495\u2013509. https:\/\/doi.org\/10.1093\/hmg\/ddr139.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"443_CR147","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1016\/j.bbamcr.2016.09.003","volume":"1863","author":"DI Kim","year":"2016","unstructured":"Kim DI, Lee KH, Gabr AA, Choi GE, Kim JS, Ko SH, et al. 108Abeta-Induced Drp1 phosphorylation through Akt activation promotes excessive mitochondrial fission leading to neuronal apoptosis. Biochim Biophys Acta. 2016;1863(11):2820\u201334. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.09.003.","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"443_CR148","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1093\/hmg\/ddr139","volume":"20","author":"M Manczak","year":"2011","unstructured":"Manczak M, Calkins MJ, Reddy PH. 109Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer\u2019s disease: implications for neuronal damage. Hum Mol Genet. 2011;20(13):2495\u2013509. https:\/\/doi.org\/10.1093\/hmg\/ddr139.","journal-title":"Hum Mol Genet"},{"key":"443_CR149","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.arr.2020.101191","volume":"64","author":"JA Pradeepkiran","year":"2020","unstructured":"Pradeepkiran JA, Reddy PH. 110Defective mitophagy in Alzheimer\u2019s disease. Ageing Res Rev. 2020;64:101191. https:\/\/doi.org\/10.1016\/j.arr.2020.101191.","journal-title":"Ageing Res Rev"},{"key":"443_CR150","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.arr.2020.101191","volume":"64","author":"JA Pradeepkiran","year":"2020","unstructured":"Pradeepkiran JA, Reddy PH. 111Defective mitophagy in Alzheimer\u2019s disease. Ageing Res Rev. 2020;64:101191. https:\/\/doi.org\/10.1016\/j.arr.2020.101191.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"443_CR151","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/15548627.2018.1532259","volume":"15","author":"J Araya","year":"2019","unstructured":"Araya J, Tsubouchi K, Sato N, Ito S, Minagawa S, Hara H, et al. 112PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis. Autophagy. 2019;15(3):510\u201326. https:\/\/doi.org\/10.1080\/15548627.2018.1532259.","journal-title":"Autophagy"},{"issue":"s1","key":"443_CR152","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.3233\/JAD-190048","volume":"72","author":"DMA Oliver","year":"2019","unstructured":"Oliver DMA, Reddy PH. 113Molecular Basis of Alzheimer\u2019s Disease: Focus on Mitochondria. J Alzheimers Dis. 2019;72(s1):S95\u2013116. https:\/\/doi.org\/10.3233\/JAD-190048.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"443_CR153","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/JAD-132543","volume":"43","author":"B Schreiner","year":"2015","unstructured":"Schreiner B, Hedskog L, Wiehager B, Ankarcrona M. 114Amyloid-beta peptides are generated in mitochondria-associated endoplasmic reticulum membranes. J Alzheimers Dis. 2015;43(2):369\u201374. https:\/\/doi.org\/10.3233\/JAD-132543.","journal-title":"J Alzheimers Dis"},{"issue":"Pt 2","key":"443_CR154","doi-asserted-by":"publisher","first-page":"130580","DOI":"10.1016\/j.ijbiomac.2024.130580","volume":"264","author":"Z Ye","year":"2024","unstructured":"Ye Z, Liu Y, Jin X, Wu Y, Zhao H, Gao T, et al. 115Abeta-binding with alcohol dehydrogenase drives Alzheimer\u2019s disease pathogenesis: A review. Int J Biol Macromol. 2024;264(Pt 2):130580. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.130580.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"443_CR155","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41420-021-00748-x","volume":"7","author":"A Saha","year":"2021","unstructured":"Saha A, Saleem S, Paidi RK, Biswas SC. 116BH3-only proteins Puma and Beclin1 regulate autophagic death in neurons in response to Amyloid-beta. Cell Death Discov. 2021;7(1):356. https:\/\/doi.org\/10.1038\/s41420-021-00748-x.","journal-title":"Cell Death Discov"},{"issue":"4","key":"443_CR156","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12264-015-1544-6","volume":"31","author":"Y Yuan","year":"2015","unstructured":"Yuan Y, Zhang X, Zheng Y, Chen Z. Regulation of mitophagy in ischemic brain injury. Neurosci Bull. 2015;31(4):395\u2013406. https:\/\/doi.org\/10.1007\/s12264-015-1544-6.","journal-title":"Neurosci Bull"},{"key":"443_CR157","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2012.06.003","volume":"246","author":"NM Kanaan","year":"2013","unstructured":"Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini GA. Axonal degeneration in Alzheimer\u2019s disease: when signaling abnormalities meet the axonal transport system. Exp Neurol. 2013;246:44\u201353. https:\/\/doi.org\/10.1016\/j.expneurol.2012.06.003.","journal-title":"Exp Neurol"},{"issue":"3","key":"443_CR158","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.tins.2017.01.002","volume":"40","author":"JS Kerr","year":"2017","unstructured":"Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, et al. Mitophagy and Alzheimer\u2019s disease: cellular and molecular mechanisms. Trends Neurosci. 2017;40(3):151\u201366. https:\/\/doi.org\/10.1016\/j.tins.2017.01.002.","journal-title":"Trends Neurosci"},{"issue":"5","key":"443_CR159","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jnc.14564","volume":"148","author":"L Bajaj","year":"2019","unstructured":"Bajaj L, Lotfi P, Pal R, Ronza AD, Sharma J, Sardiello M. Lysosome biogenesis in health and disease. J Neurochem. 2019;148(5):573\u201389. https:\/\/doi.org\/10.1111\/jnc.14564.","journal-title":"J Neurochem"},{"issue":"2","key":"443_CR160","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312\u201339. https:\/\/doi.org\/10.1016\/j.cell.2019.09.001.","journal-title":"Cell"},{"key":"443_CR161","doi-asserted-by":"publisher","unstructured":"Cummins N, Tweedie A, Zuryn S, Bertran-Gonzalez J, Gotz J. 122Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. EMBO J. 2019;38(3). https:\/\/doi.org\/10.15252\/embj.201899360.","DOI":"10.15252\/embj.201899360"},{"issue":"3","key":"443_CR162","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol. 2018;17(3):241\u201350. https:\/\/doi.org\/10.1016\/S1474-4422(18)30028-0.","journal-title":"Lancet Neurol"},{"issue":"3","key":"443_CR163","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133\u201350. https:\/\/doi.org\/10.1038\/nrneurol.2017.188.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"443_CR164","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances. Mol Neurodegener. 2020;15(1):30. https:\/\/doi.org\/10.1186\/s13024-020-00376-6.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"443_CR165","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.freeradbiomed.2022.09.032","volume":"193","author":"S Dewanjee","year":"2022","unstructured":"Dewanjee S, Chakraborty P, Bhattacharya H, Chacko L, Singh B, Chaudhary A, et al. Altered glucose metabolism in Alzheimer\u2019s disease: role of mitochondrial dysfunction and oxidative stress. Free Radic Biol Med. 2022;193(1):134\u201357. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.09.032.","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"443_CR166","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00424-020-02441-x","volume":"472","author":"H Koepsell","year":"2020","unstructured":"Koepsell H. Glucose transporters in brain in health and disease. Pflugers Arch. 2020;472(9):1299\u2013343. https:\/\/doi.org\/10.1007\/s00424-020-02441-x.","journal-title":"Pflugers Arch"},{"issue":"10","key":"443_CR167","doi-asserted-by":"publisher","first-page":"12629","DOI":"10.3390\/ijms131012629","volume":"13","author":"K Shah","year":"2012","unstructured":"Shah K, Desilva S, Abbruscato T. The role of glucose transporters in brain disease: diabetes and Alzheimer\u2019s Disease. Int J Mol Sci. 2012;13(10):12629\u201355. https:\/\/doi.org\/10.3390\/ijms131012629.","journal-title":"Int J Mol Sci"},{"key":"443_CR168","doi-asserted-by":"publisher","unstructured":"Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. 129Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview. Cells. 2023;12(16). https:\/\/doi.org\/10.3390\/cells12162019.","DOI":"10.3390\/cells12162019"},{"issue":"11","key":"443_CR169","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1002\/alz.13058","volume":"19","author":"CW Huang","year":"2023","unstructured":"Huang CW, Rust NC, Wu HF, Yin A, Zeltner N, Yin H, et al. Low glucose induced Alzheimer\u2019s disease-like biochemical changes in human induced pluripotent stem cell-derived neurons is due to dysregulated O-GlcNAcylation. Alzheimers Dement. 2023;19(11):4872\u201385. https:\/\/doi.org\/10.1002\/alz.13058.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"443_CR170","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.15252\/embj.201695810","volume":"36","author":"S Camandola","year":"2017","unstructured":"Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017;36(11):1474\u201392. https:\/\/doi.org\/10.15252\/embj.201695810.","journal-title":"EMBO J"},{"key":"443_CR171","doi-asserted-by":"publisher","first-page":"1138499","DOI":"10.3389\/fphar.2023.1138499","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Hu H, Liu X, Guo X. Hypoglycemic medicines in the treatment of Alzheimer\u2019s disease: Pathophysiological links between AD and glucose metabolism. Front Pharmacol. 2023;14:1138499. https:\/\/doi.org\/10.3389\/fphar.2023.1138499.","journal-title":"Front Pharmacol"},{"key":"443_CR172","doi-asserted-by":"publisher","first-page":"101979","DOI":"10.1016\/j.arr.2023.101979","volume":"89","author":"J Nowell","year":"2023","unstructured":"Nowell J, Blunt E, Gupta D, Edison P. Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease. Ageing Res Rev. 2023;89:101979. https:\/\/doi.org\/10.1016\/j.arr.2023.101979.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"443_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ahg.12410","volume":"85","author":"D Curtis","year":"2021","unstructured":"Curtis D, Bandyopadhyay S. Mini-review: Role of the PI3K\/Akt pathway and tyrosine phosphatases in Alzheimer\u2019s disease susceptibility. Ann Hum Genet. 2021;85(1):1\u20136. https:\/\/doi.org\/10.1111\/ahg.12410.","journal-title":"Ann Hum Genet"},{"issue":"10","key":"443_CR174","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrneurol.2010.130","volume":"6","author":"C Sims-Robinson","year":"2010","unstructured":"Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010;6(10):551\u20139. https:\/\/doi.org\/10.1038\/nrneurol.2010.130.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"443_CR175","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/db13-1954","volume":"63","author":"FG De Felice","year":"2014","unstructured":"De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014;63(7):2262\u201372. https:\/\/doi.org\/10.2337\/db13-1954.","journal-title":"Diabetes"},{"issue":"5","key":"443_CR176","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrn3012","volume":"12","author":"G Di Paolo","year":"2011","unstructured":"Di Paolo G, Kim TW. Linking lipids to Alzheimer\u2019s disease: cholesterol and beyond. Nat Rev Neurosci. 2011;12(5):284\u201396. https:\/\/doi.org\/10.1038\/nrn3012.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"443_CR177","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbalip.2014.08.011","volume":"1851","author":"G Cermenati","year":"2015","unstructured":"Cermenati G, Mitro N, Audano M, Melcangi RC, Crestani M, De Fabiani E, et al. Lipids in the nervous system: from biochemistry and molecular biology to patho-physiology. Biochim Biophys Acta. 2015;1851(1):51\u201360. https:\/\/doi.org\/10.1016\/j.bbalip.2014.08.011.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"443_CR178","doi-asserted-by":"publisher","first-page":"e1002266","DOI":"10.1371\/journal.pmed.1002266","volume":"14","author":"SG Snowden","year":"2017","unstructured":"Snowden SG, Ebshiana AA, Hye A, An Y, Pletnikova O, O\u2019Brien R, et al. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: a nontargeted metabolomic study. PLoS Med. 2017;14(3):e1002266. https:\/\/doi.org\/10.1371\/journal.pmed.1002266.","journal-title":"PLoS Med"},{"issue":"1","key":"443_CR179","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/alzrt103","volume":"4","author":"PL Wood","year":"2012","unstructured":"Wood PL. 142Lipidomics of Alzheimer\u2019s disease: current status. Alzheimers Res Ther. 2012;4(1):5. https:\/\/doi.org\/10.1186\/alzrt103.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"443_CR180","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4155\/bio.13.346","volume":"6","author":"D Touboul","year":"2014","unstructured":"Touboul D, Gaudin M. 143Lipidomics of Alzheimer\u2019s disease. Bioanalysis. 2014;6(4):541\u201361. https:\/\/doi.org\/10.4155\/bio.13.346.","journal-title":"Bioanalysis"},{"key":"443_CR181","doi-asserted-by":"publisher","unstructured":"Kao YC, Ho PC, Tu YK, Jou IM, Tsai KJ. 144Lipids and Alzheimer's Disease. Int J Mol Sci. 2020;21(4). https:\/\/doi.org\/10.3390\/ijms21041505.","DOI":"10.3390\/ijms21041505"},{"issue":"1","key":"443_CR182","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00401-012-1041-1","volume":"125","author":"AN Lazar","year":"2013","unstructured":"Lazar AN, Bich C, Panchal M, Desbenoit N, Petit VW, Touboul D, et al. Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol. 2013;125(1):133\u201344. https:\/\/doi.org\/10.1007\/s00401-012-1041-1.","journal-title":"Acta Neuropathol"},{"key":"443_CR183","doi-asserted-by":"publisher","unstructured":"Saiz-Vazquez O, Puente-Martinez A, Ubillos-Landa S, Pacheco-Bonrostro J, Santabarbara J. 146Cholesterol and Alzheimer's Disease Risk: A Meta-Meta-Analysis. Brain Sci. 2020;10(6). https:\/\/doi.org\/10.3390\/brainsci10060386.","DOI":"10.3390\/brainsci10060386"},{"issue":"4","key":"443_CR184","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1074\/jbc.M111.274142","volume":"287","author":"RB Chan","year":"2012","unstructured":"Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. 147Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem. 2012;287(4):2678\u201388. https:\/\/doi.org\/10.1074\/jbc.M111.274142.","journal-title":"J Biol Chem"},{"issue":"20","key":"443_CR185","doi-asserted-by":"publisher","first-page":"e2088","DOI":"10.1212\/WNL.0000000000009436","volume":"94","author":"MM Bernath","year":"2020","unstructured":"Bernath MM, Bhattacharyya S, Nho K, Barupal DK, Fiehn O, Baillie R, et al. Serum triglycerides in Alzheimer disease: relation to neuroimaging and CSF biomarkers. Neurology. 2020;94(20):e2088\u201398. https:\/\/doi.org\/10.1212\/WNL.0000000000009436.","journal-title":"Neurology"},{"issue":"1","key":"443_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.127","volume":"5","author":"P Proitsi","year":"2015","unstructured":"Proitsi P, Kim M, Whiley L, Pritchard M, Leung R, Soininen H, et al. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer\u2019s disease. Transl Psychiatry. 2015;5(1):e494. https:\/\/doi.org\/10.1038\/tp.2014.127.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"443_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01362-2","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Thalamuthu A, Mather KA, Crawford J, Ulanova M, Wong MWK, et al. Plasma lipidome is dysregulated in Alzheimer\u2019s disease and is associated with disease risk genes. Transl Psychiatry. 2021;11(1):344. https:\/\/doi.org\/10.1038\/s41398-021-01362-2.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"443_CR188","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.stem.2018.12.013","volume":"24","author":"R van der Kant","year":"2019","unstructured":"van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, et al. Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-\u03b2 in iPSC-Derived Alzheimer\u2019s Disease Neurons. Cell Stem Cell. 2019;24(3):363-75 e9. https:\/\/doi.org\/10.1016\/j.stem.2018.12.013.","journal-title":"Cell Stem Cell"},{"issue":"15","key":"443_CR189","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.neuron.2021.07.013","volume":"109","author":"AS Mendiola","year":"2021","unstructured":"Mendiola AS, Tognatta R, Yan Z, Akassoglou K. ApoE and immunity in Alzheimer\u2019s disease and related tauopathies: low-density lipoprotein receptor to the rescue. Neuron. 2021;109(15):2363\u20135. https:\/\/doi.org\/10.1016\/j.neuron.2021.07.013.","journal-title":"Neuron"},{"issue":"15","key":"443_CR190","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.neuron.2021.05.034","volume":"109","author":"Y Shi","year":"2021","unstructured":"Shi Y, Andhey PS, Ising C, Wang K, Snipes LL, Boyer K, et al. Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron. 2021;109(15):2413-26 e7. https:\/\/doi.org\/10.1016\/j.neuron.2021.05.034.","journal-title":"Neuron"},{"issue":"5","key":"443_CR191","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","volume":"64","author":"J Kim","year":"2009","unstructured":"Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, et al. 154Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64(5):632\u201344. https:\/\/doi.org\/10.1016\/j.neuron.2009.11.013.","journal-title":"Neuron"},{"issue":"11","key":"443_CR192","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamaneurol.2023.3530","volume":"80","author":"RN Taddei","year":"2023","unstructured":"Taddei RN, Perbet R, Mate de Gerando A, Wiedmer AE, Sanchez-Mico M, Connors Stewart T, et al. Tau Oligomer-Containing Synapse Elimination by Microglia and Astrocytes in Alzheimer Disease. JAMA Neurol. 2023;80(11):1209\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3530.","journal-title":"JAMA Neurol"},{"key":"443_CR193","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.778822","volume":"15","author":"PJ Paasila","year":"2021","unstructured":"Paasila PJ, Aramideh JA, Sutherland GT, Graeber MB. Synapses, microglia, and lipids in Alzheimer\u2019s disease. Front Neurosci. 2021;15:778822. https:\/\/doi.org\/10.3389\/fnins.2021.778822.","journal-title":"Front Neurosci"},{"issue":"3","key":"443_CR194","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jnr.22227","volume":"88","author":"R Sultana","year":"2010","unstructured":"Sultana R, Banks WA, Butterfield DA. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer\u2019s disease. J Neurosci Res. 2010;88(3):469\u201377. https:\/\/doi.org\/10.1002\/jnr.22227.","journal-title":"J Neurosci Res"},{"issue":"1","key":"443_CR195","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-022-00319-8","volume":"7","author":"S Kumar","year":"2022","unstructured":"Kumar S, Orlov E, Gowda P, Bose C, Swerdlow RH, Lahiri DK, et al. Synaptosome microRNAs regulate synapse functions in Alzheimer\u2019s disease. NPJ Genom Med. 2022;7(1):47. https:\/\/doi.org\/10.1038\/s41525-022-00319-8.","journal-title":"NPJ Genom Med"},{"key":"443_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102377","volume":"99","author":"S Dalal","year":"2024","unstructured":"Dalal S, Ramirez-Gomez J, Sharma B, Devara D, Kumar S. MicroRNAs and synapse turnover in Alzheimer\u2019s disease. Ageing Res Rev. 2024;99:102377. https:\/\/doi.org\/10.1016\/j.arr.2024.102377.","journal-title":"Ageing Res Rev"},{"key":"443_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102123","volume":"92","author":"J Rivera","year":"2023","unstructured":"Rivera J, Sharma B, Torres MM, Kumar S. Factors affecting the GABAergic synapse function in Alzheimer\u2019s disease: focus on microRNAs. Ageing Res Rev. 2023;92:102123. https:\/\/doi.org\/10.1016\/j.arr.2023.102123.","journal-title":"Ageing Res Rev"},{"issue":"10","key":"443_CR198","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1038\/s41380-019-0610-2","volume":"26","author":"N Chopra","year":"2021","unstructured":"Chopra N, Wang R, Maloney B, Nho K, Beck JS, Pourshafie N, et al. 161MicroRNA-298 reduces levels of human amyloid-beta precursor protein (APP), beta-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. Mol Psychiatry. 2021;26(10):5636\u201357. https:\/\/doi.org\/10.1038\/s41380-019-0610-2.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"443_CR199","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41380-021-01351-3","volume":"27","author":"R Wang","year":"2022","unstructured":"Wang R, Chopra N, Nho K, Maloney B, Obukhov AG, Nelson PT, et al. Human microRNA (miR-20b-5p) modulates Alzheimer\u2019s disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer\u2019s biomarkers. Mol Psychiatry. 2022;27(2):1256\u201373. https:\/\/doi.org\/10.1038\/s41380-021-01351-3.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"443_CR200","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.4103\/1673-5374.360172","volume":"18","author":"S Kumar","year":"2023","unstructured":"Kumar S. Synaptosome microRNAs: emerging synapse players in aging and Alzheimer\u2019s disease. Neural Regen Res. 2023;18(6):1275\u20136. https:\/\/doi.org\/10.4103\/1673-5374.360172.","journal-title":"Neural Regen Res"},{"issue":"12","key":"443_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165937","volume":"1866","author":"S Kumar","year":"2020","unstructured":"Kumar S, Reddy PH. The role of synaptic microRNAs in Alzheimer\u2019s disease. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165937. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165937.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"443_CR202","doi-asserted-by":"publisher","unstructured":"Siedlecki-Wullich D, Minano-Molina AJ, Rodriguez-Alvarez J. 166microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective. Cells. 2021;10(1). https:\/\/doi.org\/10.3390\/cells10010113.","DOI":"10.3390\/cells10010113"},{"key":"443_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.743573","volume":"13","author":"NZ Abuelezz","year":"2021","unstructured":"Abuelezz NZ, Nasr FE, AbdulKader MA, Bassiouny AR, Zaky A. MicroRNAs as potential orchestrators of Alzheimer\u2019s disease-related pathologies: insights on current status and future possibilities. Front Aging Neurosci. 2021;13:743573. https:\/\/doi.org\/10.3389\/fnagi.2021.743573.","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"443_CR204","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/j.bbadis.2019.06.006","volume":"1865","author":"S Kumar","year":"2019","unstructured":"Kumar S, Reddy AP, Yin X, Reddy PH. Novel MicroRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer\u2019s disease. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2428\u201340. https:\/\/doi.org\/10.1016\/j.bbadis.2019.06.006.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"443_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102182","volume":"48","author":"S Kumar","year":"2021","unstructured":"Kumar S, Morton H, Sawant N, Orlov E, Bunquin LE, Pradeepkiran JA, et al. MicroRNA-455-3p improves synaptic, cognitive functions and extends lifespan: relevance to Alzheimer\u2019s disease. Redox Biol. 2021;48:102182. https:\/\/doi.org\/10.1016\/j.redox.2021.102182.","journal-title":"Redox Biol"},{"issue":"7","key":"443_CR206","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/cns.14143","volume":"29","author":"S Li","year":"2023","unstructured":"Li S, Poon CH, Zhang Z, Yue M, Chen R, Zhang Y, et al. 174MicroRNA-128 suppresses tau phosphorylation and reduces amyloid-beta accumulation by inhibiting the expression of GSK3beta, APPBP2, and mTOR in Alzheimer\u2019s disease. CNS Neurosci Ther. 2023;29(7):1848\u201364. https:\/\/doi.org\/10.1111\/cns.14143.","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"443_CR207","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141(7):1917\u201333. https:\/\/doi.org\/10.1093\/brain\/awy132.","journal-title":"Brain"},{"issue":"9","key":"443_CR208","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/s0960-9822(95)00211-9","volume":"5","author":"R Beeri","year":"1995","unstructured":"Beeri R, Andres C, Lev-Lehman E, Timberg R, Huberman T, Shani M, et al. Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr Biol. 1995;5(9):1063\u201371. https:\/\/doi.org\/10.1016\/s0960-9822(95)00211-9.","journal-title":"Curr Biol"},{"issue":"1","key":"443_CR209","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159x13666150716165726","volume":"14","author":"TH Ferreira-Vieira","year":"2016","unstructured":"Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer\u2019s disease: targeting the Cholinergic System. Curr Neuropharmacol. 2016;14(1):101\u201315. https:\/\/doi.org\/10.2174\/1570159x13666150716165726.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"443_CR210","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12031-016-0839-z","volume":"60","author":"L Mahoney-Sanchez","year":"2016","unstructured":"Mahoney-Sanchez L, Belaidi AA, Bush AI, Ayton S. The complex role of Apolipoprotein E in Alzheimer\u2019s disease: an overview and update. J Mol Neurosci. 2016;60(3):325\u201335. https:\/\/doi.org\/10.1007\/s12031-016-0839-z.","journal-title":"J Mol Neurosci"},{"key":"443_CR211","doi-asserted-by":"publisher","unstructured":"Huang Y, Mahley RW. 187Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis. 2014;72 Pt A:3-12. https:\/\/doi.org\/10.1016\/j.nbd.2014.08.025.","DOI":"10.1016\/j.nbd.2014.08.025"},{"issue":"1","key":"443_CR212","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-f","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer\u2019s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163\u20136. https:\/\/doi.org\/10.1016\/0006-8993(91)91092-f.","journal-title":"Brain Res"},{"issue":"5","key":"443_CR213","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1074\/jbc.M005070200","volume":"276","author":"N Ohkubo","year":"2001","unstructured":"Ohkubo N, Mitsuda N, Tamatani M, Yamaguchi A, Lee YD, Ogihara T, et al. Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. J Biol Chem. 2001;276(5):3046\u201353. https:\/\/doi.org\/10.1074\/jbc.M005070200.","journal-title":"J Biol Chem"},{"issue":"1","key":"443_CR214","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. 190Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11(1):667. https:\/\/doi.org\/10.1038\/s41467-019-14279-8.","journal-title":"Nat Commun"},{"issue":"16","key":"443_CR215","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1212\/WNL.0000000000003234","volume":"87","author":"J Gonneaud","year":"2016","unstructured":"Gonneaud J, Arenaza-Urquijo EM, Fouquet M, Perrotin A, Fradin S, de La Sayette V, et al. 191Relative effect of APOE epsilon4 on neuroimaging biomarker changes across the lifespan. Neurology. 2016;87(16):1696\u2013703. https:\/\/doi.org\/10.1212\/WNL.0000000000003234.","journal-title":"Neurology"},{"issue":"10","key":"443_CR216","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1212\/WNL.0000000000004336","volume":"89","author":"YY Lim","year":"2017","unstructured":"Lim YY, Mormino EC, Alzheimer\u2019s Disease Neuroimaging I. APOE genotype and early beta-amyloid accumulation in older adults without dementia. Neurology. 2017;89(10):1028\u201334. https:\/\/doi.org\/10.1212\/WNL.0000000000004336.","journal-title":"Neurology"},{"issue":"5","key":"443_CR217","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1172\/JCI96429","volume":"128","author":"F Liao","year":"2018","unstructured":"Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest. 2018;128(5):2144\u201355. https:\/\/doi.org\/10.1172\/JCI96429.","journal-title":"J Clin Invest"},{"issue":"11","key":"443_CR218","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/1873-3468.13428","volume":"593","author":"E Hubin","year":"2019","unstructured":"Hubin E, Verghese PB, van Nuland N, Broersen K. Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation. FEBS Lett. 2019;593(11):1144\u201353. https:\/\/doi.org\/10.1002\/1873-3468.13428.","journal-title":"FEBS Lett"},{"issue":"1","key":"443_CR219","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1038\/s41467-024-49028-z","volume":"15","author":"Z Xia","year":"2024","unstructured":"Xia Z, Prescott EE, Urbanek A, Wareing HE, King MC, Olerinyova A, et al. 195Co-aggregation with Apolipoprotein E modulates the function of Amyloid-beta in Alzheimer\u2019s disease. Nat Commun. 2024;15(1):4695. https:\/\/doi.org\/10.1038\/s41467-024-49028-z.","journal-title":"Nat Commun"},{"issue":"7673","key":"443_CR220","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523\u20137. https:\/\/doi.org\/10.1038\/nature24016.","journal-title":"Nature"},{"issue":"4","key":"443_CR221","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. 197Association of Apolipoprotein E epsilon4 With Medial Temporal Tau Independent of Amyloid-beta. JAMA Neurol. 2020;77(4):470\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4421.","journal-title":"JAMA Neurol"},{"key":"443_CR222","doi-asserted-by":"publisher","unstructured":"Ferrari-Souza JP, Lussier FZ, Leffa DT, Therriault J, Tissot C, Bellaver B, et al. 199APOEepsilon4 associates with microglial activation independently of Abeta plaques and tau tangles. Sci Adv. 2023;9(14):eade1474. https:\/\/doi.org\/10.1126\/sciadv.ade1474.","DOI":"10.1126\/sciadv.ade1474"},{"issue":"9","key":"443_CR223","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41588-021-00921-z","volume":"53","author":"DP Wightman","year":"2021","unstructured":"Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. <article-title update=\"added\">A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer\u2019s disease. Nat Genet. 2021;53(9):1276\u201382. https:\/\/doi.org\/10.1038\/s41588-021-00921-z.","journal-title":"Nat Genet"},{"issue":"3","key":"443_CR224","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. 201Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414\u201330. https:\/\/doi.org\/10.1038\/s41588-019-0358-2.","journal-title":"Nat Genet"},{"issue":"4","key":"443_CR225","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. 202New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54(4):412\u201336. https:\/\/doi.org\/10.1038\/s41588-022-01024-z.","journal-title":"Nat Genet"},{"issue":"5","key":"443_CR226","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-022-02454-z","volume":"144","author":"IE Jansen","year":"2022","unstructured":"Jansen IE, van der Lee SJ, Gomez-Fonseca D, de Rojas I, Dalmasso MC, Grenier-Boley B, et al. 203Genome-wide meta-analysis for Alzheimer\u2019s disease cerebrospinal fluid biomarkers. Acta Neuropathol. 2022;144(5):821\u201342. https:\/\/doi.org\/10.1007\/s00401-022-02454-z.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"443_CR227","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","volume":"18","author":"Y Shi","year":"2018","unstructured":"Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18(12):759\u201372. https:\/\/doi.org\/10.1038\/s41577-018-0051-1.","journal-title":"Nat Rev Immunol"},{"key":"443_CR228","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57354","author":"Y Voskobiynyk","year":"2020","unstructured":"Voskobiynyk Y, Roth JR, Cochran JN, Rush T, Carullo NV, Mesina JS, et al. Alzheimer\u2019s disease risk gene BIN1 induces Tau-dependent network hyperexcitability. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.57354.","journal-title":"Elife"},{"issue":"4","key":"443_CR229","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.celrep.2016.09.063","volume":"17","author":"S Calafate","year":"2016","unstructured":"Calafate S, Flavin W, Verstreken P, Moechars D. Loss of Bin1 promotes the propagation of tau pathology. Cell Rep. 2016;17(4):931\u201340. https:\/\/doi.org\/10.1016\/j.celrep.2016.09.063.","journal-title":"Cell Rep"},{"issue":"9","key":"443_CR230","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1038\/s41380-025-02973-7","volume":"30","author":"L Jia","year":"2025","unstructured":"Jia L, Ke Y, Zhao S, Liu J, Luo X, Cao J, et al. Metagenomic analysis characterizes stage-specific gut microbiota in Alzheimer\u2019s disease. Mol Psychiatry. 2025;30(9):3951\u201362. https:\/\/doi.org\/10.1038\/s41380-025-02973-7.","journal-title":"Mol Psychiatry"},{"issue":"12","key":"443_CR231","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1093\/brain\/awad303","volume":"146","author":"S Grabrucker","year":"2023","unstructured":"Grabrucker S, Marizzoni M, Silajdzic E, Lopizzo N, Mombelli E, Nicolas S, et al. Microbiota from Alzheimer\u2019s patients induce deficits in cognition and hippocampal neurogenesis. Brain. 2023;146(12):4916\u201334. https:\/\/doi.org\/10.1093\/brain\/awad303.","journal-title":"Brain"},{"issue":"700","key":"443_CR232","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo2984","volume":"15","author":"AL Ferreiro","year":"2023","unstructured":"Ferreiro AL, Choi J, Ryou J, Newcomer EP, Thompson R, Bollinger RM, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer\u2019s disease. Sci Transl Med. 2023;15(700):eabo2984. https:\/\/doi.org\/10.1126\/scitranslmed.abo2984.","journal-title":"Sci Transl Med"},{"issue":"1","key":"443_CR233","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41283-w","volume":"14","author":"Y Xia","year":"2023","unstructured":"Xia Y, Xiao Y, Wang ZH, Liu X, Alam AM, Haran JP, et al. Bacteroides Fragilis in the gut microbiomes of Alzheimer\u2019s disease activates microglia and triggers pathogenesis in neuronal C\/EBP\u03b2 transgenic mice. Nat Commun. 2023;14(1):5471. https:\/\/doi.org\/10.1038\/s41467-023-41283-w.","journal-title":"Nat Commun"},{"issue":"11","key":"443_CR234","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1136\/gutjnl-2021-326269","volume":"71","author":"C Chen","year":"2022","unstructured":"Chen C, Liao J, Xia Y, Liu X, Jones R, Haran J, et al. Gut microbiota regulate Alzheimer\u2019s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut. 2022;71(11):2233\u201352. https:\/\/doi.org\/10.1136\/gutjnl-2021-326269.","journal-title":"Gut"},{"issue":"10","key":"443_CR235","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1038\/s41380-023-02216-7","volume":"28","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Shen Y, Liufu N, Liu L, Li W, Shi Z, et al. Transmission of Alzheimer\u2019s disease-associated microbiota dysbiosis and its impact on cognitive function: evidence from mice and patients. Mol Psychiatry. 2023;28(10):4421\u201337. https:\/\/doi.org\/10.1038\/s41380-023-02216-7.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"443_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2025.101481","volume":"17","author":"L Blackmer-Raynolds","year":"2026","unstructured":"Blackmer-Raynolds L, Lipson LD, Kozlov A, Yang A, Hill EJ, Sampson MM, et al. Indigenous gut microbes modulate neural cell state and neurodegenerative disease susceptibility. Cell Syst. 2026;17(2):101481. https:\/\/doi.org\/10.1016\/j.cels.2025.101481.","journal-title":"Cell Syst"},{"issue":"48","key":"443_CR237","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw8410","volume":"11","author":"L Li","year":"2025","unstructured":"Li L, Jia M, Yang C, Zhao Y, Hu J, Zhao Y, et al. Gut microbial-derived indole-3-propionate improves cognitive function in Alzheimer\u2019s disease. Sci Adv. 2025;11(48):eadw8410. https:\/\/doi.org\/10.1126\/sciadv.adw8410.","journal-title":"Sci Adv"},{"key":"443_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102637","volume":"104","author":"XP Zhou","year":"2025","unstructured":"Zhou XP, Sun LB, Liu WH, Zhu WM, Li LC, Song XY, et al. The complex relationship between gut microbiota and Alzheimer\u2019s disease: a systematic review. Ageing Res Rev. 2025;104:102637. https:\/\/doi.org\/10.1016\/j.arr.2024.102637.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"443_CR239","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00720-0","volume":"19","author":"YX Luo","year":"2024","unstructured":"Luo YX, Yang LL, Yao XQ. Gut microbiota-host lipid crosstalk in Alzheimer\u2019s disease: implications for disease progression and therapeutics. Mol Neurodegener. 2024;19(1):35. https:\/\/doi.org\/10.1186\/s13024-024-00720-0.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"443_CR240","doi-asserted-by":"publisher","first-page":"2167172","DOI":"10.1080\/19490976.2023.2167172","volume":"15","author":"J Jin","year":"2023","unstructured":"Jin J, Xu Z, Zhang L, Zhang C, Zhao X, Mao Y, et al. Gut-derived beta-amyloid: Likely a centerpiece of the gut-brain axis contributing to Alzheimer\u2019s pathogenesis. Gut Microbes. 2023;15(1):2167172. https:\/\/doi.org\/10.1080\/19490976.2023.2167172.","journal-title":"Gut Microbes"},{"key":"443_CR241","doi-asserted-by":"publisher","unstructured":"Gonzales MM, Garbarino VR, Pollet E, Palavicini JP, Kellogg DL, Jr., Kraig E, et al. Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Invest. 2022;132(10). https:\/\/doi.org\/10.1172\/JCI158453.","DOI":"10.1172\/JCI158453"},{"issue":"20","key":"443_CR242","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1016\/j.cell.2023.08.040","volume":"186","author":"X Xiong","year":"2023","unstructured":"Xiong X, James BT, Boix CA, Park YP, Galani K, Victor MB, et al. Epigenomic dissection of Alzheimer\u2019s disease pinpoints causal variants and reveals epigenome erosion. Cell. 2023;186(20):4422-37 e21. https:\/\/doi.org\/10.1016\/j.cell.2023.08.040.","journal-title":"Cell"},{"issue":"4","key":"443_CR243","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/13872877251322955","volume":"104","author":"T Ruan","year":"2025","unstructured":"Ruan T, Ling Y, Wu C, Niu Y, Liu G, Xu C, et al. Abnormal epigenetic modification of lysosome and lipid regulating genes in Alzheimer\u2019s disease. J Alzheimers Dis. 2025;104(4):1185\u2013200. https:\/\/doi.org\/10.1177\/13872877251322955.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"443_CR244","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02879-7","volume":"20","author":"L Wei","year":"2023","unstructured":"Wei L, Yang X, Wang J, Wang Z, Wang Q, Ding Y, et al. H3K18 lactylation of senescent microglia potentiates brain aging and Alzheimer\u2019s disease through the NF\u03baB signaling pathway. J Neuroinflammation. 2023;20(1):208. https:\/\/doi.org\/10.1186\/s12974-023-02879-7.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"443_CR245","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cmet.2022.02.013","volume":"34","author":"RY Pan","year":"2022","unstructured":"Pan RY, He L, Zhang J, Liu X, Liao Y, Gao J, et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer\u2019s disease. Cell Metab. 2022;34(4):634-48 e6. https:\/\/doi.org\/10.1016\/j.cmet.2022.02.013.","journal-title":"Cell Metab"},{"key":"443_CR246","doi-asserted-by":"publisher","unstructured":"Tian Q, Li J, Wu B, Pang Y, He W, Xiao Q, et al. APP lysine 612 lactylation ameliorates amyloid pathology and memory decline in Alzheimer's disease. J Clin Invest. 2025;135(1). https:\/\/doi.org\/10.1172\/JCI184656.","DOI":"10.1172\/JCI184656"},{"issue":"42","key":"443_CR247","doi-asserted-by":"publisher","first-page":"6954","DOI":"10.1523\/JNEUROSCI.0515-23.2023","volume":"43","author":"P Yin","year":"2023","unstructured":"Yin P, Cai Y, Cui T, Berg AJ, Wang T, Morency DT, et al. Glial sphingosine-mediated epigenetic regulation stabilizes synaptic function in Drosophila models of Alzheimer\u2019s disease. J Neurosci. 2023;43(42):6954\u201371. https:\/\/doi.org\/10.1523\/JNEUROSCI.0515-23.2023.","journal-title":"J Neurosci"},{"issue":"1","key":"443_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27572-2","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Tapias V, Acosta D, Xu H, Chen H, Bhawal R, et al. Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer\u2019s disease. Nat Commun. 2022;13(1):159. https:\/\/doi.org\/10.1038\/s41467-021-27572-2.","journal-title":"Nat Commun"},{"key":"443_CR249","doi-asserted-by":"publisher","unstructured":"Ma Y, Wang W, Liu S, Qiao X, Xing Y, Zhou Q, et al. Epigenetic Regulation of Neuroinflammation in Alzheimer's Disease. Cells. 2023;13(1). https:\/\/doi.org\/10.3390\/cells13010079.","DOI":"10.3390\/cells13010079"},{"issue":"4","key":"443_CR250","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11011-021-00846-w","volume":"37","author":"V Kakoty","year":"2022","unstructured":"Kakoty V, K CS, Dubey SK, Yang CH, Marathe SA, Taliyan R. Epigenetic regulation and autophagy modulation debilitates insulin resistance associated Alzheimer\u2019s disease condition in rats. Metab Brain Dis. 2022;37(4):927\u201344. https:\/\/doi.org\/10.1007\/s11011-021-00846-w.","journal-title":"Metab Brain Dis"},{"issue":"2","key":"443_CR251","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.stem.2023.01.002","volume":"30","author":"E Salta","year":"2023","unstructured":"Salta E, Lazarov O, Fitzsimons CP, Tanzi R, Lucassen PJ, Choi SH. Adult hippocampal neurogenesis in Alzheimer\u2019s disease: a roadmap to clinical relevance. Cell Stem Cell. 2023;30(2):120\u201336. https:\/\/doi.org\/10.1016\/j.stem.2023.01.002.","journal-title":"Cell Stem Cell"},{"issue":"10","key":"443_CR252","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1002\/alz.14179","volume":"20","author":"JN Geigenmuller","year":"2024","unstructured":"Geigenmuller JN, Tari AR, Wisloff U, Walker TL. The relationship between adult hippocampal neurogenesis and cognitive impairment in Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(10):7369\u201383. https:\/\/doi.org\/10.1002\/alz.14179.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"443_CR253","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13225","volume":"34","author":"Y Cao","year":"2024","unstructured":"Cao Y, Liu P, Bian H, Jin S, Liu J, Yu N, et al. Reduced neurogenesis in human hippocampus with Alzheimer\u2019s disease. Brain Pathol. 2024;34(3):e13225. https:\/\/doi.org\/10.1111\/bpa.13225.","journal-title":"Brain Pathol"},{"issue":"4","key":"443_CR254","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41591-019-0375-9","volume":"25","author":"EP Moreno-Jimenez","year":"2019","unstructured":"Moreno-Jimenez EP, Flor-Garcia M, Terreros-Roncal J, Rabano A, Cafini F, Pallas-Bazarra N, et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer\u2019s disease. Nat Med. 2019;25(4):554\u201360. https:\/\/doi.org\/10.1038\/s41591-019-0375-9.","journal-title":"Nat Med"},{"issue":"6571","key":"443_CR255","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1126\/science.abl5163","volume":"374","author":"J Terreros-Roncal","year":"2021","unstructured":"Terreros-Roncal J, Moreno-Jimenez EP, Flor-Garcia M, Rodriguez-Moreno CB, Trinchero MF, Cafini F, et al. Impact of neurodegenerative diseases on human adult hippocampal neurogenesis. Science. 2021;374(6571):1106\u201313. https:\/\/doi.org\/10.1126\/science.abl5163.","journal-title":"Science"},{"issue":"7919","key":"443_CR256","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-022-04912-w","volume":"607","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Su Y, Li S, Kennedy BC, Zhang DY, Bond AM, et al. Molecular landscapes of human hippocampal immature neurons across lifespan. Nature. 2022;607(7919):527\u201333. https:\/\/doi.org\/10.1038\/s41586-022-04912-w.","journal-title":"Nature"},{"issue":"4","key":"443_CR257","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.stem.2023.02.006","volume":"30","author":"YD Li","year":"2023","unstructured":"Li YD, Luo YJ, Xie L, Tart DS, Sheehy RN, Zhang L, et al. Activation of hypothalamic-enhanced adult-born neurons restores cognitive and affective function in Alzheimer\u2019s disease. Cell Stem Cell. 2023;30(4):415-32 e6. https:\/\/doi.org\/10.1016\/j.stem.2023.02.006.","journal-title":"Cell Stem Cell"},{"key":"443_CR258","doi-asserted-by":"publisher","unstructured":"Mishra R, Phan T, Kumar P, Morrissey Z, Gupta M, Hollands C, et al. Augmenting neurogenesis rescues memory impairments in Alzheimer's disease by restoring the memory-storing neurons. J Exp Med. 2022;219(9). https:\/\/doi.org\/10.1084\/jem.20220391.","DOI":"10.1084\/jem.20220391"},{"issue":"29","key":"443_CR259","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv1492","volume":"11","author":"X Yang","year":"2025","unstructured":"Yang X, Jiang W, Li Y, Lee CG, Elias JA, Tang C, et al. CHI3L1\/YKL-40 signaling inhibits neurogenesis in models of Alzheimer\u2019s disease. Sci Adv. 2025;11(29):eadv1492. https:\/\/doi.org\/10.1126\/sciadv.adv1492.","journal-title":"Sci Adv"},{"issue":"1","key":"443_CR260","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ame2.12212","volume":"5","author":"J Zheng","year":"2022","unstructured":"Zheng J. Hippocampal neurogenesis and pro-neurogenic therapies for Alzheimer\u2019s disease. Anim Model Exp Med. 2022;5(1):3\u201314. https:\/\/doi.org\/10.1002\/ame2.12212.","journal-title":"Anim Model Exp Med"},{"key":"443_CR261","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.actbio.2024.06.001","volume":"183","author":"W Zhang","year":"2024","unstructured":"Zhang W, Smith N, Zhou Y, McGee CM, Bartoli M, Fu S, et al. Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer\u2019s disease. Acta Biomater. 2024;183:341\u201355. https:\/\/doi.org\/10.1016\/j.actbio.2024.06.001.","journal-title":"Acta Biomater"},{"issue":"1","key":"443_CR262","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18. https:\/\/doi.org\/10.1186\/s13195-016-0189-7.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"443_CR263","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378(4):321\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1705971.","journal-title":"N Engl J Med"},{"issue":"7","key":"443_CR264","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med. 2021;27(7):1187\u201396. https:\/\/doi.org\/10.1038\/s41591-021-01369-8.","journal-title":"Nat Med"},{"issue":"2","key":"443_CR265","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"443_CR266","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"18","key":"443_CR267","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"issue":"10","key":"443_CR268","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(10):1015\u201324. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2793.","journal-title":"JAMA Neurol"},{"issue":"6","key":"443_CR269","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"5","key":"443_CR270","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70293","volume":"21","author":"S Salloway","year":"2025","unstructured":"Salloway S, Pain A, Lee E, Papka M, Ferguson MB, Wang H, et al. TRAILBLAZER-ALZ 4: a phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer\u2019s disease. Alzheimers Dement. 2025;21(5):e70293. https:\/\/doi.org\/10.1002\/alz.70293.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"443_CR271","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70062","volume":"21","author":"H Wang","year":"2025","unstructured":"Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimers Dement. 2025;21(4):e70062. https:\/\/doi.org\/10.1002\/alz.70062.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"443_CR272","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S1474-4422(25)00024-9","volume":"24","author":"RJ Bateman","year":"2025","unstructured":"Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer\u2019s disease: an open-label extension of the phase 2\/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol. 2025;24(4):316\u201330. https:\/\/doi.org\/10.1016\/S1474-4422(25)00024-9.","journal-title":"Lancet Neurol"},{"issue":"6","key":"443_CR273","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2024.0991","volume":"81","author":"O Wagemann","year":"2024","unstructured":"Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, et al. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA Neurol. 2024;81(6):582\u201393. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0991.","journal-title":"JAMA Neurol"},{"issue":"20","key":"443_CR274","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, et al. Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N Engl J Med. 2023;389(20):1862\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2304430.","journal-title":"N Engl J Med"},{"issue":"2","key":"443_CR275","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14414","volume":"21","author":"T Bittner","year":"2025","unstructured":"Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, et al. Biomarker treatment effects in two phase 3 trials of gantenerumab. Alzheimers Dement. 2025;21(2):e14414. https:\/\/doi.org\/10.1002\/alz.14414.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"443_CR276","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70192","volume":"21","author":"T Asada","year":"2025","unstructured":"Asada T, Thanasopoulou A, Delmar P, Wojtowicz J, Smith J, Yoshiyama Y, et al. Japanese participant data from three gantenerumab trials in early Alzheimer\u2019s disease. Alzheimers Dement. 2025;21(4):e70192. https:\/\/doi.org\/10.1002\/alz.70192.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"443_CR277","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79(11):1113\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2909.","journal-title":"JAMA Neurol"},{"issue":"7","key":"443_CR278","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","volume":"84","author":"JA Hey","year":"2024","unstructured":"Hey JA, Abushakra S, Blennow K, Reiman EM, Hort J, Prins ND, et al. Effects of oral ALZ-801\/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer\u2019s disease. Drugs. 2024;84(7):811\u201323. https:\/\/doi.org\/10.1007\/s40265-024-02067-8.","journal-title":"Drugs"},{"issue":"4","key":"443_CR279","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100082","volume":"12","author":"EN Cline","year":"2025","unstructured":"Cline EN, Antwi-Berko D, Sundell K, Johnson E, Hyland M, Zhang H, et al. Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2025;12(4):100082. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100082.","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"443_CR280","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med. 2023;389(12):1096\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa2305032.","journal-title":"N Engl J Med"},{"issue":"1","key":"443_CR281","doi-asserted-by":"publisher","first-page":"65","DOI":"10.14283\/jpad.2024.2","volume":"11","author":"M Cantillon","year":"2024","unstructured":"Cantillon M, Andreasen N, Prins N. Phase 1\/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2024;11(1):65\u201370. https:\/\/doi.org\/10.14283\/jpad.2024.2.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"443_CR282","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01490-z","volume":"16","author":"D Galasko","year":"2024","unstructured":"Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, et al. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):151. https:\/\/doi.org\/10.1186\/s13195-024-01490-z.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"443_CR283","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41582-025-01123-5","volume":"21","author":"MS Rafii","year":"2025","unstructured":"Rafii MS, Aisen PS. Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2025;21(9):490\u20138. https:\/\/doi.org\/10.1038\/s41582-025-01123-5.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"443_CR284","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):322\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1304839.","journal-title":"N Engl J Med"},{"issue":"4","key":"443_CR285","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):311\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1312889.","journal-title":"N Engl J Med"},{"issue":"21","key":"443_CR286","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","volume":"90","author":"JL Cummings","year":"2018","unstructured":"Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889\u201397. https:\/\/doi.org\/10.1212\/WNL.0000000000005550.","journal-title":"Neurology"},{"issue":"1","key":"443_CR287","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00465-w","volume":"14","author":"BH Kim","year":"2025","unstructured":"Kim BH, Kim S, Nam Y, Park YH, Shin SM, Moon M. Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives. Transl Neurodegener. 2025;14(1):6. https:\/\/doi.org\/10.1186\/s40035-025-00465-w.","journal-title":"Transl Neurodegener"},{"issue":"4","key":"443_CR288","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/brain\/awae345","volume":"148","author":"LA Welikovitch","year":"2025","unstructured":"Welikovitch LA, Mate de Gerando A, Khasnavis A, Bhavsar H, Meltzer JC, Buee L, et al. Tau, synapse loss and gliosis progress in an Alzheimer\u2019s mouse model after amyloid-\u03b2 immunotherapy. Brain. 2025;148(4):1316\u201328. https:\/\/doi.org\/10.1093\/brain\/awae345.","journal-title":"Brain"},{"issue":"7618","key":"443_CR289","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136. https:\/\/doi.org\/10.1038\/nature19323.","journal-title":"Nature"},{"issue":"5","key":"443_CR290","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/alz.13755","volume":"20","author":"T Chen","year":"2024","unstructured":"Chen T, O\u2019Gorman J, Castrillo-Viguera C, Rajagovindan R, Curiale GG, Tian Y, et al. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab. Alzheimers Dement. 2024;20(5):3406\u201315. https:\/\/doi.org\/10.1002\/alz.13755.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"443_CR291","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-021-00557-x","volume":"17","author":"KY Liu","year":"2021","unstructured":"Liu KY, Howard R. Can we learn lessons from the FDA\u2019s approval of aducanumab? Nat Rev Neurol. 2021;17(11):715\u201322. https:\/\/doi.org\/10.1038\/s41582-021-00557-x.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"443_CR292","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jama.2022.24490","volume":"329","author":"HD Larkin","year":"2023","unstructured":"Larkin HD. Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA. 2023;329(5):363. https:\/\/doi.org\/10.1001\/jama.2022.24490.","journal-title":"JAMA"},{"issue":"6","key":"443_CR293","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jama.2023.12548","volume":"330","author":"E Harris","year":"2023","unstructured":"Harris E. Alzheimer Drug Lecanemab Gains Traditional FDA Approval. JAMA. 2023;330(6):495. https:\/\/doi.org\/10.1001\/jama.2023.12548.","journal-title":"JAMA"},{"issue":"10","key":"443_CR294","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70750","volume":"21","author":"S Chen","year":"2025","unstructured":"Chen S, Ou R, Wei Q, Li C, Song W, Zhao B, et al. Lecanemab treatment for Alzheimer\u2019s Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China. Alzheimers Dement. 2025;21(10):e70750. https:\/\/doi.org\/10.1002\/alz.70750.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"443_CR295","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70347","volume":"21","author":"A McCullough","year":"2025","unstructured":"McCullough A, Chen CD, Gordon BA, Joseph-Mathurin N, Jack CR Jr., Koeppe R, et al. Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial. Alzheimers Dement. 2025;21(7):e70347. https:\/\/doi.org\/10.1002\/alz.70347.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"443_CR296","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004568","volume":"22","author":"R Tonegawa-Kuji","year":"2025","unstructured":"Tonegawa-Kuji R, Hou Y, Hu B, Lorincz-Comi N, Pieper AA, Tousi B, et al. Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer\u2019s disease: a systematic review and meta-analysis. PLoS Med. 2025;22(3):e1004568. https:\/\/doi.org\/10.1371\/journal.pmed.1004568.","journal-title":"PLoS Med"},{"issue":"1","key":"443_CR297","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00401-025-02892-5","volume":"149","author":"F Liao","year":"2025","unstructured":"Liao F, Calvo-Rodriguez M, Chhaya M, Sefrin JP, Charych EI, Mezler M, et al. Anti-pyroglutamate-3 Abeta immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Abeta amyloidosis. Acta Neuropathol. 2025;149(1):55. https:\/\/doi.org\/10.1007\/s00401-025-02892-5.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"443_CR298","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, et al. Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17(1):14. https:\/\/doi.org\/10.1186\/s13195-024-01666-7.","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"443_CR299","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","volume":"80","author":"AL Edwards","year":"2023","unstructured":"Edwards AL, Collins JA, Junge C, Kordasiewicz H, Mignon L, Wu S, et al. Exploratory Tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2023;80(12):1344\u201352. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3861.","journal-title":"JAMA Neurol"},{"issue":"8","key":"443_CR300","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","volume":"79","author":"E Teng","year":"2022","unstructured":"Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, et al. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2022;79(8):758\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1375.","journal-title":"JAMA Neurol"},{"issue":"14","key":"443_CR301","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, et al. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: lauriet. Neurology. 2023;101(14):e1391-e401. https:\/\/doi.org\/10.1212\/WNL.0000000000207663.","journal-title":"Neurology"},{"key":"443_CR302","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105940","volume":"120","author":"O Sol","year":"2025","unstructured":"Sol O, Mermoud J, Hallikainen M, Kurl S, Rinne J, Dautzenberg P, et al. Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer\u2019s disease: a phase 1b\/2a, multicentre, double-blind, randomised, placebo-controlled study. EBioMedicine. 2025;120:105940. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105940.","journal-title":"EBioMedicine"},{"issue":"3","key":"443_CR303","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/WAD.0000000000000680","volume":"39","author":"S Rawal","year":"2025","unstructured":"Rawal S, Wildsmith KR, Aluri J, Yagi T, Chang MK, Niu H, et al. An anti-tau therapeutic antibody etalanetug (E2814): a phase 1, first-in-human (FIH) study of single and multiple ascending doses in healthy subjects. Alzheimer Dis Assoc Disord. 2025;39(3):151\u20137. https:\/\/doi.org\/10.1097\/WAD.0000000000000680.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"443_CR304","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","volume":"28","author":"N Basheer","year":"2023","unstructured":"Basheer N, Smolek T, Hassan I, Liu F, Iqbal K, Zilka N, et al. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From preclinical studies to the clinical trials. Mol Psychiatry. 2023;28(6):2197\u2013214. https:\/\/doi.org\/10.1038\/s41380-023-02113-z.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"443_CR305","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2025.108685","volume":"120","author":"S Gambhir","year":"2025","unstructured":"Gambhir S, Singh M. Advancing Alzheimer\u2019s therapeutics via in silico strategies: tideglusib based multi-target analogues. Comput Biol Chem. 2025;120(2):108685. https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108685.","journal-title":"Comput Biol Chem"},{"issue":"6","key":"443_CR306","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1021\/acschemneuro.2c00476","volume":"14","author":"B Amaral","year":"2023","unstructured":"Amaral B, Capacci A, Anderson T, Tezer C, Bajrami B, Lulla M, et al. Elucidation of the GSK3alpha Structure Informs the Design of Novel. ACS Chem Neurosci. 2023;14(6):1080\u201394. https:\/\/doi.org\/10.1021\/acschemneuro.2c00476.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"443_CR307","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70112","volume":"11","author":"AG Gildengers","year":"2025","unstructured":"Gildengers AG, Ibrahim TS, Zeng X, Aizenstein HJ, Alkhateeb SK, Anderson SJ, et al. The LATTICE study: design of a pilot feasibility randomized controlled trial of lithium to delay cognitive decline in mild cognitive impairment. Alzheimers Dement (N Y). 2025;11(2):e70112. https:\/\/doi.org\/10.1002\/trc2.70112.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10","key":"443_CR308","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1111\/febs.70021","volume":"292","author":"RX Santos","year":"2025","unstructured":"Santos RX, Lee SH, Lofthouse R, Melis V, Robinson L, Leith M, et al. Hydromethylthionine sustains truncated tau-dependent inflammation-lowering effects in mouse brain. FEBS J. 2025;292(10):2602\u201323. https:\/\/doi.org\/10.1111\/febs.70021.","journal-title":"FEBS J"},{"key":"443_CR309","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111269","volume":"121","author":"AL Cranston","year":"2024","unstructured":"Cranston AL, Kraev I, Stewart MG, Horsley D, Santos RX, Robinson L, et al. Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine. Cell Signal. 2024;121:111269. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111269.","journal-title":"Cell Signal"},{"issue":"3","key":"443_CR310","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70101","volume":"21","author":"NM Maphis","year":"2025","unstructured":"Maphis NM, Hulse J, Peabody J, Dadras S, Whelpley MJ, Kandath M, et al. Targeting of phosphorylated tau at threonine 181 by a Qbeta virus-like particle vaccine is safe, highly immunogenic, and reduces disease severity in mice and rhesus macaques. Alzheimers Dement. 2025;21(3):e70101. https:\/\/doi.org\/10.1002\/alz.70101.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"443_CR311","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/brain\/awad024","volume":"146","author":"H Florian","year":"2023","unstructured":"Florian H, Wang D, Arnold SE, Boada M, Guo Q, Jin Z, et al. Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study. Brain. 2023;146(6):2275\u201384. https:\/\/doi.org\/10.1093\/brain\/awad024.","journal-title":"Brain"},{"issue":"6","key":"443_CR312","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s43587-024-00630-2","volume":"4","author":"M Sarazin","year":"2024","unstructured":"Sarazin M, Lagarde J, El Haddad I, de Souza LC, Bellier B, Potier MC, et al. The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer\u2019s disease. Nat Aging. 2024;4(6):761\u201370. https:\/\/doi.org\/10.1038\/s43587-024-00630-2.","journal-title":"Nat Aging"},{"issue":"6","key":"443_CR313","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41591-024-02977-w","volume":"30","author":"HRC Shanks","year":"2024","unstructured":"Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, et al. p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial. Nat Med. 2024;30(6):1761\u201370. https:\/\/doi.org\/10.1038\/s41591-024-02977-w.","journal-title":"Nat Med"},{"issue":"1","key":"443_CR314","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01817-4","volume":"17","author":"B Budda","year":"2025","unstructured":"Budda B, Mitra A, Park L, Long H, Kurnellas M, Bien-Ly N, et al. Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17(1):174. https:\/\/doi.org\/10.1186\/s13195-025-01817-4.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"443_CR315","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/alz.12302","volume":"17","author":"NJ Izzo","year":"2021","unstructured":"Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, et al. Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer\u2019s disease modification. Alzheimers Dement. 2021;17(8):1365\u201382. https:\/\/doi.org\/10.1002\/alz.12302.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"443_CR316","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70537","volume":"21","author":"M Nuytten","year":"2025","unstructured":"Nuytten M, Voets M, Debroux E, Princen K, Pringels L, Fivaz M, et al. Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer\u2019s disease. Alzheimers Dement. 2025;21(9):e70537. https:\/\/doi.org\/10.1002\/alz.70537.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"443_CR317","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70704","volume":"21","author":"JM Erichsen","year":"2025","unstructured":"Erichsen JM, Register TC, Sutphen C, Ma D, Gaussoin SA, Rudolph M, et al. A phase 2A\/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD. Alzheimers Dement. 2025;21(10):e70704. https:\/\/doi.org\/10.1002\/alz.70704.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"443_CR318","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","volume":"15","author":"B Dubois","year":"2023","unstructured":"Dubois B, Lopez-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, et al. Masitinib for mild-to-moderate Alzheimer\u2019s disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther. 2023;15(1):39. https:\/\/doi.org\/10.1186\/s13195-023-01169-x.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"443_CR319","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):235. https:\/\/doi.org\/10.1186\/s13195-024-01599-1.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"443_CR320","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaneurol.2024.3733","volume":"82","author":"S Ayton","year":"2025","unstructured":"Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, et al. Deferiprone in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2025;82(1):11\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3733.","journal-title":"JAMA Neurol"},{"issue":"1","key":"443_CR321","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01791-x","volume":"17","author":"A Faridar","year":"2025","unstructured":"Faridar A, Gamez N, Li D, Wang Y, Boradia R, Thome AD, et al. Low-dose interleukin-2 in patients with mild to moderate Alzheimer\u2019s disease: a randomized clinical trial. Alzheimers Res Ther. 2025;17(1):146. https:\/\/doi.org\/10.1186\/s13195-025-01791-x.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"443_CR322","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14283\/jpad.2021.62","volume":"9","author":"MM Gonzales","year":"2022","unstructured":"Gonzales MM, Garbarino VR, Marques Zilli E, Petersen RC, Kirkland JL, Tchkonia T, et al. Senolytic Therapy to Modulate the Progression of Alzheimer\u2019s Disease (SToMP-AD): A Pilot Clinical Trial. The Journal of Prevention of Alzheimer\u2019s Disease. 2022;9(1):22\u20139. https:\/\/doi.org\/10.14283\/jpad.2021.62.","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"4","key":"443_CR323","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00591","volume":"22","author":"VR Garbarino","year":"2025","unstructured":"Garbarino VR, Palavicini JP, Melendez J, Barthelemy NR, He Y, Kautz TF, et al. Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer\u2019s disease. Neurotherapeutics. 2025;22(4):e00591. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00591.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"443_CR324","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0298-9","volume":"13","author":"M Gratuze","year":"2018","unstructured":"Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer\u2019s disease. Mol Neurodegener. 2018;13(1):66. https:\/\/doi.org\/10.1186\/s13024-018-0298-9.","journal-title":"Mol Neurodegener"},{"key":"443_CR325","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2025.1576020","volume":"17","author":"YN Ma","year":"2025","unstructured":"Ma YN, Hu X, Karako K, Song P, Tang W, Xia Y. The potential and challenges of TREM2-targeted therapy in Alzheimer\u2019s disease: insights from the INVOKE-2 study. Front Aging Neurosci. 2025;17:1576020. https:\/\/doi.org\/10.3389\/fnagi.2025.1576020.","journal-title":"Front Aging Neurosci"},{"issue":"43","key":"443_CR326","doi-asserted-by":"publisher","first-page":"37617","DOI":"10.1021\/acsnano.5c08317","volume":"19","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li J, Zhang D, Feng Y, Zhou M, Zhou C, et al. Modulating amyloid pathology-neural hyperexcitability crosstalk for Alzheimer\u2019s disease therapy. ACS Nano. 2025;19(43):37617\u201332. https:\/\/doi.org\/10.1021\/acsnano.5c08317.","journal-title":"ACS Nano"},{"issue":"10","key":"443_CR327","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","volume":"28","author":"A Feigin","year":"2022","unstructured":"Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, et al. Pepinemab antibody blockade of SEMA4D in early Huntington\u2019s disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022;28(10):2183\u201393. https:\/\/doi.org\/10.1038\/s41591-022-01919-8.","journal-title":"Nat Med"},{"issue":"12","key":"443_CR328","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40263-025-01226-z","volume":"39","author":"C Holscher","year":"2025","unstructured":"Holscher C. Incretin hormones GLP-1 and GIP normalize energy utilization and reduce inflammation in the brain in Alzheimer\u2019s disease and Parkinson\u2019s disease: from repurposed GLP-1 receptor agonists to novel dual GLP-1\/GIP receptor agonists as potential disease-modifying therapies. CNS Drugs. 2025;39(12):1201\u201320. https:\/\/doi.org\/10.1007\/s40263-025-01226-z.","journal-title":"CNS Drugs"},{"issue":"1","key":"443_CR329","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05165-3","volume":"12","author":"D Kellar","year":"2022","unstructured":"Kellar D, Register T, Lockhart SN, Aisen P, Raman R, Rissman RA, et al. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer\u2019s disease: a randomized trial. Sci Rep. 2022;12(1):1346. https:\/\/doi.org\/10.1038\/s41598-022-05165-3.","journal-title":"Sci Rep"},{"issue":"3","key":"443_CR330","doi-asserted-by":"publisher","first-page":"240","DOI":"10.14283\/jpad.2021.14","volume":"8","author":"D Kellar","year":"2021","unstructured":"Kellar D, Lockhart SN, Aisen P, Raman R, Rissman RA, Brewer J, et al. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2021;8(3):240\u20138. https:\/\/doi.org\/10.14283\/jpad.2021.14.","journal-title":"J Prev Alzheimers Dis"},{"issue":"9","key":"443_CR331","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70639","volume":"21","author":"P Zhang","year":"2025","unstructured":"Zhang P, Mao C, Sun A, Yang Y, Hou Y, Fu Z, et al. Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer\u2019s disease. Alzheimers Dement. 2025;21(9):e70639. https:\/\/doi.org\/10.1002\/alz.70639.","journal-title":"Alzheimers Dement"},{"key":"443_CR332","doi-asserted-by":"publisher","unstructured":"Zhang Z, Deng W, Hu L, Hu Y, Zhang S, Xiong Y, et al. Zinc homeostasis imbalance: Potential therapeutic value in neurodegenerative diseases. Neural Regen Res. 2025. https:\/\/doi.org\/10.4103\/NRR.NRR-D-25-00632.","DOI":"10.4103\/NRR.NRR-D-25-00632"},{"key":"443_CR333","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1412356","volume":"18","author":"M Scholefield","year":"2024","unstructured":"Scholefield M, Church SJ, Xu J, Cooper GJS. Metallomic analysis of brain tissues distinguishes between cases of dementia with Lewy bodies, Alzheimer\u2019s disease, and Parkinson\u2019s disease dementia. Front Neurosci. 2024;18:1412356. https:\/\/doi.org\/10.3389\/fnins.2024.1412356.","journal-title":"Front Neurosci"},{"key":"443_CR334","doi-asserted-by":"publisher","unstructured":"Squitti R, Benussi A, Fostinelli S, Geviti A, Rivolta J, Ventriglia M, et al. Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial. Biomolecules. 2025;15(9). https:\/\/doi.org\/10.3390\/biom15091268.","DOI":"10.3390\/biom15091268"},{"issue":"1","key":"443_CR335","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02460-0","volume":"23","author":"S Shukla","year":"2025","unstructured":"Shukla S, Kadam AA, Goyani S, Jaiswal N, Samantaray K, Kashyap S, et al. Cell-type-specific dysregulation of mitochondrial calcium signaling in Alzheimer\u2019s disease. Cell Commun Signal. 2025;23(1):472. https:\/\/doi.org\/10.1186\/s12964-025-02460-0.","journal-title":"Cell Commun Signal"},{"issue":"8081","key":"443_CR336","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-025-09335-x","volume":"645","author":"L Aron","year":"2025","unstructured":"Aron L, Ngian ZK, Qiu C, Choi J, Liang M, Drake DM, et al. Lithium deficiency and the onset of Alzheimer\u2019s disease. Nature. 2025;645(8081):712\u201321. https:\/\/doi.org\/10.1038\/s41586-025-09335-x.","journal-title":"Nature"},{"issue":"1","key":"443_CR337","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-026-00541-9","volume":"15","author":"J Liao","year":"2026","unstructured":"Liao J, Mou H, Luo S, Shen L, Jiao B. Microbiota and Alzheimer\u2019s disease: mechanistic insights from a multi-organ perspective. Transl Neurodegener. 2026;15(1):3. https:\/\/doi.org\/10.1186\/s40035-026-00541-9.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"443_CR338","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cmet.2024.10.006","volume":"37","author":"X Zha","year":"2025","unstructured":"Zha X, Liu X, Wei M, Huang H, Cao J, Liu S, et al. Microbiota-derived lysophosphatidylcholine alleviates Alzheimer\u2019s disease pathology via suppressing ferroptosis. Cell Metab. 2025;37(1):169-86 e9. https:\/\/doi.org\/10.1016\/j.cmet.2024.10.006.","journal-title":"Cell Metab"},{"issue":"1","key":"443_CR339","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-024-02001-w","volume":"13","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang C, Yuan B, Liu L, Zhang H, Zhu M, et al. Akkermansia muciniphila and its metabolite propionic acid maintains neuronal mitochondrial division and autophagy homeostasis during Alzheimer\u2019s disease pathologic process via GPR41 and GPR43. Microbiome. 2025;13(1):16. https:\/\/doi.org\/10.1186\/s40168-024-02001-w.","journal-title":"Microbiome"},{"issue":"1","key":"443_CR340","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01880-x","volume":"18","author":"B Wang","year":"2026","unstructured":"Wang B, Pan M, Yang L, Xu J, Ye C, Li Y, et al. <article-title update=\"added\">Akkermansia muciniphila reduces neuroinflammation and A\u03b2 deposition via tryptophan metabolism in the APP\/PS1 mouse model of Alzheimer\u2019s disease. Alzheimers Res Ther. 2026;18(1):41. https:\/\/doi.org\/10.1186\/s13195-025-01880-x.","journal-title":"Alzheimers Res Ther"},{"key":"443_CR341","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1706811","volume":"17","author":"L Peng","year":"2026","unstructured":"Peng L, Zhang Z, Hu Y, Chen H, Tian Y, Ling H. Regulating the crosstalk between Bifidobacterium and the brain: a potential therapeutic strategy for Alzheimer\u2019s disease. Front Immunol. 2026;17:1706811. https:\/\/doi.org\/10.3389\/fimmu.2026.1706811.","journal-title":"Front Immunol"},{"issue":"2","key":"443_CR342","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70006","volume":"4","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Jia M, Ding C, Bao B, Li H, Ma J, et al. Time-restricted feeding mitigates Alzheimer\u2019s disease-associated cognitive impairments via a B. pseudolongum-propionic acid-FFAR3 axis. Imeta. 2025;4(2):e70006. https:\/\/doi.org\/10.1002\/imt2.70006.","journal-title":"Imeta"},{"key":"443_CR343","doi-asserted-by":"publisher","unstructured":"Levak N, Lehtisalo J, Thunborg C, Westman E, Andersen P, Andrieu S, et al. Nutrition guidance within a multimodal intervention improves diet quality in prodromal Alzheimer's disease: Multimodal Preventive Trial for Alzheimer's Disease (MIND-AD(mini)). Alzheimers Res Ther. 2024;16(1):147. https:\/\/doi.org\/10.1186\/s13195-024-01522-8.","DOI":"10.1186\/s13195-024-01522-8"},{"key":"443_CR344","doi-asserted-by":"publisher","unstructured":"Hoscheidt S, Sanderlin AH, Baker LD, Jung Y, Lockhart S, Kellar D, et al. Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial. Alzheimers Dement. 2022;18(3):457-68. https:\/\/doi.org\/10.1002\/alz.12421.","DOI":"10.1002\/alz.12421"},{"key":"443_CR345","doi-asserted-by":"publisher","unstructured":"Fekete M, Varga P, Ungvari Z, Fekete JT, Buda A, Szappanos A, et al. The role of the Mediterranean diet in reducing the risk of cognitive impairement, dementia, and Alzheimer's disease: a meta-analysis. Geroscience. 2025;47(3):3111-30. https:\/\/doi.org\/10.1007\/s11357-024-01488-3.","DOI":"10.1007\/s11357-024-01488-3"},{"key":"443_CR346","doi-asserted-by":"publisher","unstructured":"Dilmore AH, Martino C, Neth BJ, West KA, Zemlin J, Rahman G, et al. Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease. Alzheimers Dement. 2023;19(11):4805-16. https:\/\/doi.org\/10.1002\/alz.13007.","DOI":"10.1002\/alz.13007"},{"issue":"11","key":"443_CR347","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s43587-022-00311-y","volume":"2","author":"RY Pan","year":"2022","unstructured":"Pan RY, Zhang J, Wang J, Wang Y, Li Z, Liao Y, et al. Intermittent fasting protects against Alzheimer\u2019s disease in mice by altering metabolism through remodeling of the gut microbiota. Nat Aging. 2022;2(11):1024\u201339. https:\/\/doi.org\/10.1038\/s43587-022-00311-y.","journal-title":"Nat Aging"},{"issue":"1","key":"443_CR348","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2323752","volume":"16","author":"G Park","year":"2024","unstructured":"Park G, Kadyan S, Hochuli N, Pollak J, Wang B, Salazar G, et al. A modified mediterranean-style diet enhances brain function via specific gut-microbiome-brain mechanisms. Gut Microbes. 2024;16(1):2323752. https:\/\/doi.org\/10.1080\/19490976.2024.2323752.","journal-title":"Gut Microbes"},{"issue":"2","key":"443_CR349","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jshs.2023.07.003","volume":"13","author":"CS Norevik","year":"2024","unstructured":"Norevik CS, Huuha AM, Rosbjorgen RN, Hildegard Bergersen L, Jacobsen K, Miguel-Dos-Santos R, et al. Exercised blood plasma promotes hippocampal neurogenesis in the Alzheimer\u2019s disease rat brain. J Sport Health Sci. 2024;13(2):245\u201355. https:\/\/doi.org\/10.1016\/j.jshs.2023.07.003.","journal-title":"J Sport Health Sci"},{"issue":"10","key":"443_CR350","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.7150\/thno.81951","volume":"13","author":"S Feng","year":"2023","unstructured":"Feng S, Wu C, Zou P, Deng Q, Chen Z, Li M, et al. High-intensity interval training ameliorates Alzheimer\u2019s disease-like pathology by regulating astrocyte phenotype-associated AQP4 polarization. Theranostics. 2023;13(10):3434\u201350. https:\/\/doi.org\/10.7150\/thno.81951.","journal-title":"Theranostics"},{"key":"443_CR351","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jare.2024.03.025","volume":"69","author":"Y Chen","year":"2025","unstructured":"Chen Y, Chen X, Luo Z, Kang X, Ge Y, Wan R, et al. Exercise-induced reduction of IGF1R sumoylation attenuates neuroinflammation in APP\/PS1 transgenic mice. J Adv Res. 2025;69:279\u201397. https:\/\/doi.org\/10.1016\/j.jare.2024.03.025.","journal-title":"J Adv Res"},{"issue":"1","key":"443_CR352","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00497-2","volume":"14","author":"Y Chen","year":"2025","unstructured":"Chen Y, Cai J, She Y, He X, Feng H, Li X, et al. Long-term exercise enhances meningeal lymphatic vessel plasticity and drainage in a mouse model of Alzheimer\u2019s disease. Transl Neurodegener. 2025;14(1):37. https:\/\/doi.org\/10.1186\/s40035-025-00497-2.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"443_CR353","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202304545","volume":"11","author":"P Mondal","year":"2024","unstructured":"Mondal P, Bai P, Gomm A, Bakiasi G, Lin CJ, Wang Y, et al. Structure-based discovery of a small molecule inhibitor of histone deacetylase 6 (HDAC6) that significantly reduces Alzheimer\u2019s disease neuropathology. Adv Sci (Weinh). 2024;11(1):e2304545. https:\/\/doi.org\/10.1002\/advs.202304545.","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"443_CR354","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00739","volume":"22","author":"C Liu","year":"2025","unstructured":"Liu C, Zhao Y, Dao JJ, Zhang W, Liu J, Ma YK, et al. Targeted ErbB4 receptor activation ameliorates neuronal deficits via DOCK3 signaling in a transgenic mouse AD model. Neurotherapeutics. 2025;22(6):e00739. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00739.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"443_CR355","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14509","volume":"30","author":"Y Lee","year":"2024","unstructured":"Lee Y, Ju YJ, Gee MS, Jeon SH, Kim N, Koo T, et al. Survivin enhances hippocampal neurogenesis and cognitive function in Alzheimer\u2019s disease mouse model. CNS Neurosci Ther. 2024;30(4):e14509. https:\/\/doi.org\/10.1111\/cns.14509.","journal-title":"CNS Neurosci Ther"},{"key":"443_CR356","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2026.106117","volume":"193","author":"P Zhao","year":"2026","unstructured":"Zhao P, Cao Z, Rozpedek-Kaminska W. Receptor tyrosine kinases in Alzheimer\u2019s disease: mechanistic insights and therapeutic implications. Neurochem Int. 2026;193:106117. https:\/\/doi.org\/10.1016\/j.neuint.2026.106117.","journal-title":"Neurochem Int"},{"key":"443_CR357","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jare.2025.04.025","volume":"80","author":"Y Zhao","year":"2026","unstructured":"Zhao Y, Zhao W, Chai X, Sun P, Huang J, Guo X, et al. Reshaping the gut microbiota: a novel oppinion of Eucommiae cortex polysaccharide alleviate learning and memory impairments in Alzheimer\u2019s disease. J Adv Res. 2026;80:219\u201337. https:\/\/doi.org\/10.1016\/j.jare.2025.04.025.","journal-title":"J Adv Res"},{"key":"443_CR358","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.132372","volume":"270","author":"C He","year":"2024","unstructured":"He C, Jiang J, Liu J, Zhou L, Ge Y, Yang Z. Pseudostellaria heterophylla polysaccharide mitigates Alzheimer\u2019s-like pathology via regulating the microbiota-gut-brain axis in 5 x FAD mice. Int J Biol Macromol. 2024;270:132372. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.132372.","journal-title":"Int J Biol Macromol"},{"issue":"20","key":"443_CR359","doi-asserted-by":"publisher","first-page":"8140","DOI":"10.1039\/d5fo03048j","volume":"16","author":"JD Chen","year":"2025","unstructured":"Chen JD, Chen SY, Liao CC, Fang CY, Yen GC. Enhancing cognitive memory function using Phyllanthus emblica polysaccharides via modulating autophagy and reshaping the gut microbiota. Food Funct. 2025;16(20):8140\u201359. https:\/\/doi.org\/10.1039\/d5fo03048j.","journal-title":"Food Funct"},{"key":"443_CR360","doi-asserted-by":"publisher","unstructured":"Li Y, Wang H, Zhang D, Wang S, Li Z, Li J, et al. Gut microbiota-dependent 24-hydroxycholesterol metabolism contributes to capsaicin-induced amelioration of Alzheimer's disease-like pathology in mice. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-68937-9.","DOI":"10.1038\/s41467-026-68937-9"},{"key":"443_CR361","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154956","volume":"118","author":"S Yang","year":"2023","unstructured":"Yang S, Fan L, Zhang R, Song C, Shi J, Wang J, et al. Smilagenin induces expression and epigenetic remodeling of BDNF in alzheimer\u2019s disease. Phytomedicine. 2023;118:154956. https:\/\/doi.org\/10.1016\/j.phymed.2023.154956.","journal-title":"Phytomedicine"},{"key":"443_CR362","doi-asserted-by":"publisher","unstructured":"Lou S, Gong D, Yang M, Qiu Q, Luo J, Chen T. Curcumin Improves Neurogenesis in Alzheimer's Disease Mice via the Upregulation of Wnt\/beta-Catenin and BDNF. Int J Mol Sci. 2024;25(10). https:\/\/doi.org\/10.3390\/ijms25105123.","DOI":"10.3390\/ijms25105123"},{"key":"443_CR363","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155802","volume":"131","author":"Y Sun","year":"2024","unstructured":"Sun Y, Zhang H, Liu R, Wang Y, Zhang X, Huang R, et al. Zexieyin formula alleviates Alzheimer\u2019s disease via post-synaptic CaMKII modulating AMPA receptor: involved in promoting neurogenesis to strengthen synaptic plasticity in mice hippocampus. Phytomedicine. 2024;131:155802. https:\/\/doi.org\/10.1016\/j.phymed.2024.155802.","journal-title":"Phytomedicine"},{"key":"443_CR364","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117462","volume":"321","author":"L She","year":"2024","unstructured":"She L, Tang H, Zeng Y, Li L, Xiong L, Sun J, et al. Ginsenoside RK3 promotes neurogenesis in Alzheimer\u2019s disease through activation of the CREB\/BDNF pathway. J Ethnopharmacol. 2024;321:117462. https:\/\/doi.org\/10.1016\/j.jep.2023.117462.","journal-title":"J Ethnopharmacol"},{"issue":"9","key":"443_CR365","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1039\/d2fo03191d","volume":"14","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Yang X, Liu J, Song J, Zhang S, Chen L, et al. 20S-protopanaxatriol improves cognitive function of Alzheimer\u2019s disease by promoting endogenous neurogenesis. Food Funct. 2023;14(9):4191\u2013203. https:\/\/doi.org\/10.1039\/d2fo03191d.","journal-title":"Food Funct"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00443-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00443-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00443-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:02:11Z","timestamp":1775167331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00443-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":365,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00443-2","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}